From:	Boos, Terrence L.
Sent:	Wed, 1 Aug 2012 13:59:22 -0400
To:	Rannazzisi, Joseph T.;Hill, Robert L.;Rannazzisi, Joseph T.;Hill, Robert L.
Subject:	data sources
Attachments:	Katz_Osteoarthritis_2008.pdf, PROP Cautious Evidnce Based Prescribing.pdf,

PolicyImpact-PrescriptionPainkillerOD.pdf, Manchikanti_ASIPP Opioid Guidelines_2012.pdf,
Dhalla_BMJ_2011.pdf, andrewkolodny-_RXDrugSummit.pdf

I have spoken with Bobby a few times today regarding trends in opioid overdose deaths and ED visits and attempted to pull some info.

Attached are some possible data sources to mirror CDC's methadone report. Please see Katz paper (2008), table 1 provides a great overview of data sources.

Also, Dr. Kolodny's presentation from the RX Drug Summit highlights TEDS data.

Anticipate you may have already visited these sources; therefore, if there are any specifics that can be provided in framing the issue, please let me know. Terry

Abuse-deterrent Opioid Formulations: Are They a Pipe Dream?

Nathaniel Katz, MD

Corresponding author
Nathaniel Katz, MD
Analgesic Research, 109 Highland Avenue, Suite B2,
Needham, MA 02494, USA.
E-mail: nkatz@analgesicresearch.com

The continued need for opioids to treat pain and their unavoidable link to abuse and addiction create a need for risk mitigation approaches that optimize their risk–benefit ratio. Abuse-deterrent formulations (ADFs) have emerged as a means for supporting opioid access while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist–antagonist formulations, aversion, prodrugs, and alternative methods of administration. Each of these types has the potential to reduce specific forms of prescription opioid abuse. ADFs have the potential to reduce the public health burden of prescription opioid abuse, but they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.

Introduction

Few medical problems have persisted and have been characterized by as much confusion, rancor, inconsistent terminology, data misinterpretation, conflation with sociologic myths, and lack of evidence as the issue of prescription opioid abuse. Discussions about whether the therapeutic value of opioids is outweighed by their abuse potential can be found as far back as 300 BC. The obvious solution—developing a strong nonaddictive analgesic—has met with no success despite millennia of ethnobotanical efforts and decades of modern drug development. Opioid risk management refers to efforts designed to maximize the benefit–risk balance of opioids given their flaws [1••]. Abuse-deterrent formulations (ADFs) of strong opioids have the potential to provide a modicum of balance in the effort to relieve pain while minimizing abuse, because in principle, they support access to opioids while minimizing certain types of abuse. This review focuses on whether this ADF principle can be translated into practice.

Terminology

Some progress has been made in achieving consensus on terms related to prescription opioid abuse [2•], but more work remains. The terms abuse and misuse are very widely used, but with different meanings by different authors. A recent working group adopted definitions used in this review [3••], and those follow upon other precedents. Misuse refers to inappropriate use of a medication but for a medical purpose rather than for mind-altering effects. Examples include unauthorized dose escalation for pain treatment, cutting extended-release (ER) formulations for faster analgesic onset or to save money, or sharing the medication with others in pain. Abuse is an umbrella term referring to the use of a medication for its mind-altering effects, whether or not one also has pain or has been prescribed the medication. Both abuse and misuse may also constitute noncompliance if one has received a prescription with instructions not to engage in the forbidden behaviors. Several important phenomena do not fall neatly into either abuse or misuse, such as suicide attempts and accidental pediatric ingestion.

In this paper, ADF will be used to denote opioid formulations incorporating features that may deter one or more common forms of prescription opioid abuse or misuse or may minimize the harm resulting from such behaviors. This term is used rather than "abuse-resistant" after a recent meeting on the subject concluded that "resistance" may imply a degree of infallibility of these products that is unsupported by current data [3••].

Public Health Consequences of Prescription Opioid Abuse

Determining whether an ADF actually deters abuse requires quantification of the public health consequences of abuse, misuse, and related phenomena (Table 1). The links between these phenomena and the measurable public health events used to quantify them are presented here.

Table 1. Inappropriate behaviors related to prescription opioids to measurable public health events

Concept	Measurable public health event	Examples of data sources
Abuse	Nonmedical use	NSDUH
	Abuse	NSDUH
	Addiction	NSDUH
	Abuse of specific products	NAVIPPRO
	Entries into treatment for prescription opioid addiction	NAVIPPRO, TEDS
	New initiates to nonmedical prescription opioid use	NSDUH
	Nonmedical use among youth	MTF, NSDUH
	Altered route of ingestion of prescription opioids (eg, intravenous, nasal)	NAVIPPRO, TEDS
	Poisoning related to abuse	TESS, RADARS, DAWN
	Emergency department visits related to abuse	DAWN
Abuse or misuse	Opioid-related hospitalizations	NCHS
	Prescription opioid deaths	DAWN, coroners' databases, NCHS
Misuse	Misuse episodes	Direct patient surveys*
	Poisonings related to misuse	TESS, RADARS
	ED visits related to misuse	DAWN
Suicide	Prescription opioid suicide attempts	DAWN
Accidental pediatric ingestion	Pediatric exposures	TESS, RADARS
	Fatal pediatric exposures	TESS, RADARS

*None published to the author's knowledge.
DAWN—Drug Abuse Warning Network; MTF—Monitoring the Future; NAVIPPRO—National Addictions Vigilance Intervention and Prevention Program; NCHS—National Center for Health Statistics; NSDUH—National Survey on Drug Use and Health; RADARS— Researched Abuse, Diversion and Addiction-Related Surveillance; TEDS—Treatment Episode Data Set; TESS—Toxic Exposure Surveillance System.

Abuse

Abuse encompasses a spectrum of behaviors that to some extent fall along a continuum. Use for mind-altering effects may be called "nonmedical use" (further qualified by frequency of use) [4••], and is often called "recreational use." This may lead to loss of control and compulsive use despite negative consequences. The Diagnostic and Statistical Manual of Mental Disorders (DSM) divides these substance use disorders into "abuse" and "dependence," with the latter more severe than the former [5] and more appropriately called "addiction" [6]. Irrespective of the terminology, the key observation remains that some users progress, and preventing this progression is a central public health target.

Almost all early users ingest their medications orally with or without chewing [7]. As abuse progresses, users increasingly modify the route of ingestion, frequently snorting then injecting [7]. Frequency of use and daily dose may increase, and consequences may become more severe along a number of domains such as medical (eg, HIV, hepatitis), legal, and employment [8]. Altering the route of ingestion may also accelerate the progression of addiction by increasing the total exposure and the rate of onset [9,10]. Sources of diverted medications also shift, with early users obtaining medications primarily from friends and family [4••], and advanced users more commonly obtaining medications from dealers, doctor shopping, stealing, and other less socially acceptable methods [11].

Many of these features of abuse constitute measurable public health events. Lifetime, past year, and past month nonmedical use of prescription opioids are assessed annually in the United States [4••]. In 2006, a projected 33.5 million Americans aged 12 years or older used a prescription opioid nonmedically at least once; 12.6 million used in the past year, and 5.2 million in the past month. More than 1.6 million individuals were projected to meet DSM criteria for abuse or dependence. Although these data are useful for prescription opioids as a class, at least initially, ADFs are not likely to affect prescription opioid abuse overall, but are more likely to reduce abuse of specific products. A different database called the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO) has been set up to provide product-specific indices of prescription opioid abuse [12]. NAVIPPRO indicates, for example, that approximately 70% of individuals in treatment for prescription opioid abuse indicate past month nonmedical use of hydrocodone, by far the leading product overall; about 40% indicate past month use of oxycodone-ER, the leading ER product among abusers [12].

Of great importance for ADFs is monitoring altered routes of ingestion. For example, the NAVIPPRO database

indicates that among users of oxycodone-ER, 51% ingest it orally, 45% snort it, and 29% inject it; for morphine ER the percentages are 30%, 25%, and 60%, respectively (Stephen Butler, PhD, Inflexxion, Newton, MA, personal communication). By contrast, only 1% of hydrocodone users inject the drug. Such data can be used to validate an "injection-resistant" ADF, which would be expected to show a low number of individuals altering the oral formulation for intravenous injection. Also, such data can be used to determine what types of ADFs are needed. For example, it would seem pointless to develop an injection-proof formulation of hydrocodone, because few if any users inject it.

Other important and measurable indices of prescription opioid abuse include new initiates to prescription opioid abuse (2.2 million in 2006, ahead of all other illicit drugs) [4••], nonmedical use among youth (9% of 12th graders used a prescription opioid nonmedically in 2006) [13•], poison control center calls (nearly 300,000 related to analgesics in 2004) [14•], emergency department visits (over 130,000 related to prescription opioids in 2004) [15••], and others. Such reports arise from both abuse and misuse, and although some systems attempt to disentangle these causes, the exact behavioral antecedent often is unclear or difficult to classify. Nonetheless, such indices can be used in a targeted manner to evaluate the potential impact of ADFs on these manifestations of abuse and misuse.

Misuse

The consequences of misuse, if reported at all, may appear as a poison control center call, an emergency department visit, an opioid-related hospitalization, a spontaneous adverse event report, or an opioid-related death. By the time those types of reports occur, it may be unclear whether abuse, misuse, or something else led to the incident. To measure the impact of an ADF on misuse, one can use surveillance data (to the extent that the events are classified as misuse), or one can conduct direct patient surveys on misuse. To this author's knowledge, no direct surveys of opioid misuse have been published, although studies of aberrant behaviors are conceptually akin to misuse surveys and could be adapted for this purpose [16].

Several aspects of public health data likely reflect misuse. National mortality data indicate that the rate of unintentional poisoning deaths related to opioids has increased by 91% from 1999 to 2002, to a rate of approximately 100 per 10 million people per year [17•]. According to the Toxic Exposure Surveillance System poison control center database, analgesics were the leading cause of poisoning deaths in 2004, with 654 deaths reported to this specific system; analgesics were also the leading cause of poisonings overall, numbering nearly 300,000 in the same year [14•]. Deaths associated with prescription opioids in the Drug Abuse Warning Network (DAWN) database increased annually from 1997 to 2002, with 1294 deaths reported in the most recent year of that

report [18]. DAWN also provides data on the rate of emergency department visits associated with prescription opioids, which numbered 132,207 in 2004. More specific categorizations of these events as misuse related are possible but not presented here.

Suicide

Suicide does not fit neatly under abuse or misuse as defined herein, because the individual attempting suicide is generally not using the medication for medical purposes at the time (misuse) or for mind-altering effects (abuse). In the United States, over 9% of high school students attempt suicide each year (approximately 1.3 million suicide attempts annually). The leading substance implicated in these events is prescription opioids, which are involved in 36% of the events [19]. Although it is unclear how an ADF would decrease opioid-related suicide attempts, perhaps ADFs could be developed to be safer in overdose or in coingestion with alcohol, a common accompaniment of intentional (or unintentional) overdose.

Accidental pediatric ingestion

Accidental pediatric ingestion is among the most feared and mourned mishaps related to prescription opioids, and it is one of the chief risk management concerns of the US Food and Drug Administration (FDA). Analgesics are the leading pharmaceutical class associated with accidental pediatric ingestion in the United States; in 2004, they were responsible for 98,237 pediatric exposures, exceeded only by cosmetics, personal care products, and cleaning substances [14•]. Again, it is unclear how ADFs alone will deter accidental pediatric exposure, but it is conceivable that ADFs formulated to be safer in overdose could reduce the proportion of such events that are fatal.

Types of Abuse-deterrent Formulations

A number of opioids have been introduced over the past century amid claims of being less subject to abuse only to create epidemics of abuse, including heroin and Talwin (Hospira, Lake Forest, IL) [20,21•]. Indeed, other opioids such as tramadol and buprenorphine appear to be abused less frequently, but they do not seem as useful for severe pain as the full μ-agonist opioids. Thus, most attempts to develop ADFs have focused on formulating μ-agonist opioids in such a manner as to prevent common types of abuse, or at least to reduce the harmful consequences of such behaviors. These strategies can be grouped into several different subtypes, although some efforts do not fit neatly into these categories, and other efforts comprise multiple strategies in the same formulation. The major ADF types are discussed below without an attempt to be comprehensive.

Physical barriers

Common methods of tampering with prescription opioids consist of—in order of increasing effort required—simple

Table 2. Abuse-deterrent formulations and their potential ability to mitigate different types of abuse*

Type of abuse	Physical barriers	Agonist–antagonist	Aversion	Prodrug	Alternative routes of administration
Intravenous	+	+	+	+	+
Snorting	+	+	+	-	+
Chewing	+	+	+	-	+
Alcohol interaction	+/-	+/-	-	-	+
Intact abuse	-	-	+/-	+	-
Misuse	+/-	+/-	-	+	-

*The purpose of this table is not to present specific benefits of formulations, but rather to illustrate that different formulations will have specific effects on different abuse types, depending upon the exact nature of the formulation.
(+)—potential benefit; (-)—no likely benefit; (+/-)—possible benefit, depending on the specifics of the formulation or the exact nature of the type of abuse/misuse.

physical manipulations (eg, chewing, crushing), single-step chemical manipulations (eg, dissolving in water or alcohol), multistep chemical manipulations (eg, dissolving in alcohol then redissolving in water), and laboratory extractions, which are rarely conducted "in the street" these days [22•,23].

Several companies have announced programs to develop formulations that resist common methods of tampering, although to this author's knowledge, none of these original research results have been published in the peer-reviewed scientific literature. Several are in late-stage clinical development. Remoxy (King Pharmaceuticals, Bristol, TN, and Pain Therapeutics, San Mateo, CA) is an ER formulation of oxycodone that appears to resist a number of common forms of physical and chemical tampering, and has been tested in several pharmacokinetic studies and at least one clinical trial [24]. A formulation with similar effects in resisting physical and chemical manipulation was presented by scientists from Grunenthal (Germany) at a meeting of the College of Problems in Drug Dependency in April 2005 [25]. A third company, Collegium Pharmaceutical (Cumberland, RI), filed a patent, announced the development of such an ADF, and recently announced a positive clinical proof-of-concept study [26], although further information is not available. No doubt other such efforts are also underway.

Another formulation that appears to deter abuse is already on the market, known as Osmotic Release Oral System (OROS) [27]. Methylphenidate is marketed in this formulation for attention deficit hyperactivity disorder under the brand name Concerta (ALZA, Mountain View, CA, and McNeil Pediatrics, Fort Washington, PA). The OROS formulation has been shown to resist common forms of physical and chemical tampering, and several lines of evidence suggest that Concerta has a lower abuse liability than immediate-release methylphenidate and possibly other long-acting formulations of methylphenidate in both experimental [27] and real-world [28] settings. An OROS formulation of hydromorphone is currently in late-stage clinical development. This author is unaware of

published data on the extent to which OROS hydromorphone may resist common forms of tampering.

Table 2 provides a framework for considering the potential public health benefits of physical barrier–type ADFs. The most direct benefit would be reduced ingestion by alternate routes of the parent product. If overall prescribing of ER products shifts to specific ADFs, there may be a reduction of altered ingestion of prescription opioids as a class. Secondary benefits could include reduction of injection-related diseases, reduction in the rate of development of addiction, and potentially reduced rates of other health events. These ADFs may also diminish consequences of misuse that involve tampering (such as inadvertently chewing an ER formulation). These formulations are not expected to reduce the rates or consequences of ingestion of intact oral formulations, perhaps the most common type of abuse.

Agonist–antagonist combinations

Several formulations containing opioids in combination with opioid antagonists for the purpose of deterring abuse are already on the market in the United States and elsewhere [21•]. In response to widespread abuse of pentazocine (Talwin) in the 1970s, the manufacturer replaced Talwin with Talwin NX, a combination of 50 mg of pentazocine and 0.5 mg of naloxone. Because naloxone has very poor oral bioavailability, the expectation was that when taken orally, the naloxone would have no impact on analgesia but that when injected, the naloxone would be sufficient to eliminate the euphoria or produce frank withdrawal. Indeed, Talwin's abuse rate appeared to drop precipitously after the introduction of Talwin NX, although several authors have suggested that the decline in abuse of Talwin was more related to a surge in availability of cheap heroin at the time, an argument bolstered by case reports of addicts who habitually injected Talwin NX [29].

Valoron (tilidine, Pfizer, New York, NY) is an opioid analgesic that began to be abused in Germany and other countries in the late 1970s [21•]. The manufacturer then

launched a combination product, Valoron N, containing 50 mg of tilidine and 4 mg of naloxone, to deter intravenous abuse. Valoron N monitoring has generated little evidence of abuse, but it is unclear whether this is due to the addition of naloxone, because most abuse of tilidine was oral (not intravenous), and presumably not affected by naloxone.

Buprenorphine is a partial μ-opioid agonist used as an analgesic and as maintenance treatment for opioid addiction in many countries around the world. Buprenorphine was approved for the treatment of opioid addiction in the United States under the brand Subutex (Reckitt Benckiser Pharmaceuticals, Berkshire, UK) in 2003. Because buprenorphine had been widely abused intravenously in other countries, Suboxone (Reckitt Benckiser Pharmaceuticals), a product consisting of buprenorphine and naloxone in a 4:1 ratio, was approved simultaneously with Subutex [21•]. Although pharmacologic studies show mixed results with regard to reduction in abuse liability by the added naloxone, published reports suggest that the combination may be less desirable to addicts than the single-entity product [30]. Data on the relative abuse rate of Subutex and Suboxone exist [31], but to this author's knowledge, these data have not been published. Thus, Suboxone provides a third example of a successful agonist–antagonist formulation marketed to deter abuse, without sufficient publicly available data to support firm conclusions about effectiveness.

Several companies have announced development programs of new opioid agonist–antagonist combinations. Alpharma (Bridgewater, NJ) recently presented data from a phase 2 clinical trial on an ER morphine product containing sequestered naltrexone demonstrating that the combination product relieved pain without significant "leakage" of naltrexone, a major technical challenge in the development of sequestered antagonist formulations [32]. Elite Pharmaceuticals (Northvale, NJ) has also presented human pharmacokinetic data on its ADF, oxycodone with sequestered naltrexone, reporting that untampered product did not release naltrexone, whereas the tampered product did [33].

Aversion

A review of patent literature and corporate announcements indicates an alternative approach: opioid products containing an additional substance that produces some type of unpleasant effect in patients who ingest tampered product [34,35]. One approach involves incorporating capsaicin, a component of hot chili peppers. If swallowed whole, the capsaicin would not produce any effects; however, if the product were crushed and snorted, dissolved and injected, or inhaled, the capsaicin would produce an intense burning discomfort that would leave one uninterested in a repeat experience. A second approach combines an opioid (oxycodone) with niacin, which if taken in excessive doses, produces a classic niacin reaction consisting of warmth, flushing, and other uncomfortable symptoms that resolve in 1 to 2 hours [36]. Although

press releases and similar materials indicate that positive clinical proof-of-concept studies have been completed for these products, to the author's knowledge, no such trials have been published.

The aversion approach raises a number of issues. One issue is whether the aversive effects could occur occasionally in patients who take the medication as directed, or who unwittingly take the medication inappropriately, such as by chewing or cutting the product. In such cases, would physicians prescribe a product that adds only risk to the compliant patient, in order to deter inappropriate behavior by abusers? The second, more fundamental question is whether physical punishment will be considered by prescribers and by consumers to be an appropriate means of deterring individuals from abusing medications.

Prodrugs

A prodrug is a drug with little or no pharmacologic effect until it is metabolized to an active form after ingestion. At a minimum, this feature may result in a delay in reaching maximum plasma concentrations of the active ingredient and therefore decrease reinforcing effects. If the specific metabolic systems are saturable, after a certain dose, further biotransformation to active form cannot occur, thus reducing both maximal euphoria and possibly the risk of respiratory depression in overdose. In fact, codeine appears to be a prodrug, because its analgesic effect and presumably euphoria result primarily from metabolism to morphine. New River Pharmaceuticals, recently acquired by Shire (Hampshire, UK), announced such an approach [35]. NRP-290 is a lysine-modified opioid prodrug that requires a biotransformation step to become active. The activation of the prodrug by enzymatic cleavage is said to be limited to the gastrointestinal tract, and conversion is said not to occur with intravenous or intranasal administration. To date, to the author's knowledge, no clinical trials demonstrating proof-of-concept for this product have been presented or published.

However, a predecessor product, also from Shire and based on this technology has been developed, approved, and launched in the United States. The product, Vyvanse (lisdexamfetamine dimesylate), is a conjugate of dextroamphetamine and L-lysine, which is metabolized to dextroamphetamine apparently by first-pass intestinal and/or hepatic metabolism, and is approved for the treatment of attention deficit hyperactivity disorder [37]. Human studies demonstrated relatively less subjective effects compared to equivalent doses of dextroamphetamine, consistent with a delayed time of maximum concentration but which could be overcome by increasing the Vyvanse dose. Unfortunately, no pharmacologic studies have been published demonstrating an asymptote of exposure at increasing doses.

Alternative methods of administration

Certain products, by virtue of the formulation's design to support the intended route of administration, seem rela-

tively abuse deterrent. For example, transdermal fentanyl products, though certainly abused, are mentioned at only a fraction of the rate of other ER opioids in abuse surveillance data [15••,38]. The key feature of abuse deterrence of these products is that it is simply more difficult and more dangerous to convert the drug in a transdermal patch to the rapid-onset, supratherapeutic but nonlethal dose desired by abusers. Differences are likely to exist among products that further render one transdermal product more attractive to abusers than another [39]. Such features include the amount of drug left after the patch has been used, ease of dividing the medication in the product into precisely metered doses, ease of extracting the active ingredient into a usable rapid-onset form, and "environmental" factors such as cost, availability, and reputation. Several companies are developing other transdermal products such as transdermal buprenorphine, and if studied appropriately, these products may turn out to have abuse-deterrent properties.

Other novel delivery approaches in development may prove even more resistant to abuse. For example, Titan Pharmaceuticals (South San Francisco, CA) has announced a program to develop a subcutaneous implant—insertable during an office procedure—that would release an opioid continuously for several months [40]. Other companies have announced development programs focused on injections that would release opioid for over a month [21•,41]. Such implants, which would be essentially impossible to abuse, could have a role in treating patients with comorbid substance abuse and chronic pain, a subgroup that probably accounts for 20% to 40% of the chronic pain population on opioid therapy [42,43•].

Will Abuse-deterrent Formulations Achieve Their Public Health Potential?

Several conditions seem necessary for ADFs to realize their public health benefits. First, they must be studied appropriately, so their abuse-deterrent properties can be verified [3••]. Otherwise, the FDA will not allow promotion of abuse-deterrent properties, payers will not pay for the medications, and clinicians will not prescribe them. The bench top testing, preclinical testing, human clinical pharmacology studies, and even clinical trials, however promising, are all surrogate measures for the outcome measure of actual interest: real-world abuse. Although surrogate measures may be sufficient to support preliminary prescribing decisions, they can only be validated in postmarketing epidemiologic studies or large clinical trials.

Second, earlier generation, more abusable opioids must become relatively unavailable. Most abusers obtain their medications directly or indirectly from physicians' prescriptions [4••], but many abusers, particularly those most severely addicted, obtain their medications through sources such as dealers, theft, cross-border smuggling, and the Internet. Abuse among this latter group would not be expected to change based on some clinicians shifting to prescribing ADFs, and it would not be affected until shifts in prescribing had been so complete as to make the more abusable opioids unavailable. The good news is that this is an achievable and perhaps inevitable goal.

A third consideration is that all the foreseeable ADFs address only parts of the prescription opioid abuse problem. To a great extent, benefits will be product specific. For example, an oxycodone-ER ADF would have more impact on the abuse of oxycodone-ER than on that of transdermal fentanyl or immediate-release oxycodone. Moreover, benefits will be specific to the type of abuse deterred by the formulation. Most ADFs are focused on preventing tampering. Unfortunately, most prescription opioid abuse involves ingestion of intact formulations and would not be mitigated by these ADFs. Table 2 presents a conceptual schema for the types of prescription opioid abuse that are likely to be deterred by specific formulation approaches, which can be linked to the public health outcomes in Table 1.

Conclusions

Intravenous injection and nasal ingestion of prescription opioid formulations are likely to be the subtypes of abuse most directly impacted by the first ADFs. Given the ubiquity of street access to injectable ER formulations, public health benefits of such ADFs likely will not be felt until the injectable formulations are no longer readily available. ADFs of immediate-release opioids, such as prodrugs or aversive formulations, will be needed to address the larger problem of ingestion of intact immediate-release formulations; to date, little data have been presented on such products.

Nonetheless, we are entering a promising new era in which an iterative process of developing opioid formulations to deter aspects of prescription opioid abuse, rationally and systematically evaluating their real-world effectiveness, and then improving upon their design, will bring us closer to realizing the twin goals of addressing undertreated pain while simultaneously minimizing consequent harm.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- •   Of importance
- ••   Of major importance

1.•• Katz NP, Adams EH, Benneyan JC, et al.: **Foundations of opioid risk management.** *Clin J Pain* 2007, **23**:103–118.
Provides the only available overview of opioid risk management, summarizing the goals, key stakeholders, and most important approaches.

2.•   Savage S, Covington EC, Heit HA, et al.: **Definitions related to the use of opioids for the treatment of pain. American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, 2007.** Available at http://www.ampainsoc.org/advocacy/opioids2.htm. Accessed November 28, 2007.
Consensus statement on the definitions of physical dependence, tolerance, and addiction.

3.•• Katz NP, Adams EH, Chilcoat H, et al.: **Challenges in the development of prescription opioid abuse-deterrent formulations.** *Clin J Pain* 2007, **23**:648–660.
Provides a comprehensive overview of the challenges in developing ADFs.

4.•• *Substance Abuse and Mental Health Services Administration: Results from the 2006 National Survey on Drug Use and Health: National Findings. (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293).* Rockville, MD: Department of Health and Human Services; 2007.
Provides the most comprehensive picture available of prescription opioid abuse in the United States, including unique data on the sources of diverted prescription opioids.

5.   American Psychiatric Association: *Diagnostic and Statistical Manual of Mental Disorders,* 4 edn, text revision. Washington, DC: American Psychiatric Association; 2000.

6.   O'Brien CP, Volkow N, Li TK: **What's in a word? Addiction vs. dependence in DSM-V.** *Am J Psychiatry* 2006, **163**:764–765.

7.   Hays LR: **A profile of OxyContin addiction.** *J Addict Dis* 2004, **23**:1–9.

8.   White AG, Birnbaum HG, Mareva MN, et al.: **Direct costs of opioid abuse in an insured population in the United States.** *J Manag Care Pharm* 2005, **11**:469–479.

9.   Compton WM, Volkow ND: **Abuse of prescription drugs and the risk of addiction.** *Drug Alcohol Depend* 2006, **83(Suppl 1)**:S4–7.

10. Marsch LA, Bickel WK, Badger GJ, et al.: **Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.** *J Pharmacol Exp Ther* 2001, **299**:1056–1065.

11. Rosenblum A, Parrino M, Schnoll SH, et al.: **Prescription opioid abuse among enrollees into methadone maintenance treatment.** *Drug Alcohol Depend* 2007, **90**:64–71.

12. Butler S, Budman S, Villapiano A, et al.: **The NAVIPPRO System: new data on the feasibility of real-time, product specific opioid surveillance.** *Presented at the American Pain Society Annual Meeting.* Washington, DC; May 5–7, 2007.

13.• Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: *Monitoring the future national results on adolescent drug use: overview of key findings, 2006. (NIH Publication No. 07-6202).* Bethesda, MD: National Institute on Drug Abuse; 2007.
Provides the key data on drug abuse among US youth.

14.• Watson WA, Litovitz TL, Rodgers GC Jr, et al.: **2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.** *Am J Emerg Med* 2005, **23**:589–666.
Most recent report available from the Toxic Exposure Surveillance System, which highlights in detail the ways in which prescription opioid abuse and misuse may be illuminated by poison control data.

15.•• *Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2005: National estimates of drug-related emergency department visits. (DAWN Series D-29, DHHS Publication No. SMA 07-4256.)* Rockville, MD: Department of Health and Human Services; 2007.
Most recent DAWN report, which provides critical information about prescription opioid abuse as viewed through the lens of the emergency department.

16. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK: **Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse.** *Clin J Pain* 2006, **22**:173–181.

17.• Paulozzi LJ, Ryan GW: **Opioid analgesics and rates of fatal drug poisoning in the United States.** *Am J Prev Med* 2006, **31**:506–511.
Illuminates the recent dramatic rise in poisoning deaths related to prescription opioids in the United States.

18. *Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2003: area profiles of drug-related mortality. (DAWN Series D-27, DHHS Publication No. SMA 05-4023.)* Rockville, MD: Department of Health and Human Services; 2005.

19. *Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Disposition of emergency department visits for drug-related suicide attempts by adolescents: 2004. The New DAWN Report. Issue 6.* Rockville, MD: Department of Health and Human Services; 2006.

20. Booth M: *Opium: A History.* New York: St. Martins Press; 1996.

21.• Fudala PJ, Johnson RE: **Development of opioid formulations with limited diversion and abuse potential.** *Drug Alcohol Depend* 2006, **83(Suppl 1)**:S40–47.
Excellent review of the history of ADFs, including detailed discussion of the agonist-antagonist preparations.

22.• Katz NP, Buse DC, Budman SH, et al.: **Development and preliminary experience with an ease of extractability rating system for prescription opioids.** *Drug Dev Ind Pharm* 2006, **32**:727–746.
A study summarizing how prescription opioid abusers extract opioids from marketed products. The paper also provides the only public proposal for a standard battery to assess the extractability of an opioid formulation.

23. Cone EJ: **Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.** *Drug Alcohol Depend* 2006, **83(Suppl 1)**:S31–39.

24. Webster LR: **PTI-821: sustained-release oxycodone using gel-cap technology.** *Expert Opin Investig Drugs* 2007, **16**:359–366.

25. Bartholomaeus J, Arkenau E, Ashworth JB: **A new technology to increase the mechanical stability of matrix tablets to prevent abuse by crushing or chewing.** *Presented at the College of Problems in Drug Dependency.* Bethesda, MD; April 19-20, 2005.

26. **Collegium Pharmaceutical: Central nervous system.** Available at http://www.collegiumpharma.com/products/cns.html. Accessed November 28, 2007.

27. Parasrampuria DA, Schoedel KA, Schuller R, et al.: **Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.** *J Clin Psychopharmacol* 2007, **27**:459–467.

28. Teter CJ, McCabe SE, LaGrange K, et al.: **Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.** *Pharmacotherapy* 2006, **26**:1501–1510.

29. Lahmeyer HW, Craig RJ: **Pentazocine–naloxone: another "addiction-proof" drug of abuse.** *Int J Addict* 1987, **22**:1163–1166.

30. Alho H, Sinclair D, Vuori E, Holopainen A: **Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.** *Drug Alcohol Depend* 2007, 88:75–78.

31. **US Food and Drug Administration, Center for Drug Evaluation and Research: Subutex and Suboxone: questions and answers.** Available at http://www.fda.gov/cder/drug/ infopage/subutex_suboxone/subutex-qa.htm. Accessed November 28, 2007.

32. Katz N, Sun S, Fox L, et al.: **Treatment of osteoarthritis pain with extended-release morphine sulfate plus seques-tered naltrexone ASA 2007 Annual Meeting [abstract #652984].** *Presented at the American Society of Anesthesi-ologists.* San Francisco, CA; October 15, 2007.

33. Elite Pharmaceuticals Inc.: **Home page.** Available at www. elitepharma.com. Accessed November 28, 2007.

34. Woolf CJ, Hashmi M: **Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.** *Curr Opin Investig Drugs* 2004, 5:61–66.

35. Gershell L, Goater JJ: **From the analyst's couch: making gains in pain.** *Nat Rev Drug Discov* 2006, 5:889–890.

36. Acura Pharmaceuticals Inc.: **Home page.** Available at http:// www.acurapharm.com. Accessed November 28, 2007.

37. *Vyvanse* [package insert]. Hampshire, UK: Shire Pharma-ceuticals; 2007.

38. Rosenblum A, Parrino M, Schnoll SH, et al.: **Prescription opioid abuse among enrollees into methadone maintenance treatment.** *Drug Alcohol Depend* 2007, 90:64–71.

39. Butler SF, Benoit CM, Budman SH, et al.: **Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers.** *Harm Reduct J* 2006, 3:5.

40. Bell J, White J, Saunders J, et al.: **PROBUPHINE (buprenor-phine implant) provides sustained serum buprenorphine concentrations and long-term control of withdrawal symptoms and cravings [poster].** *Presented at the College on Problems of Drug Dependence 66th Annual Scientific Meeting.* San Juan, Puerto Rico; June 12–17, 2004.

41. Sobel BF, Sigmon SC, Walsh SL, et al.: **Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.** *Drug Alcohol Depend* 2004, 73:11–22.

42. Katz N, Fanciullo GJ: **Role of urine toxicology testing in the management of chronic opioid therapy.** *Clin J Pain* 2002, 18(4 Suppl):S76–82.

43.• Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.: **Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.** *BMC Health Serv Res* 2006, 6:46. One of the only prospective studies designed to determine the inci-dence of prescription opioid abuse (called "misuse" in the paper) among patients prescribed opioids for chronic pain.

Cautious, Evidence-Based Opioid Prescribing

Despite low-quality evidence supporting practice change,[1-6] use of chronic opioid therapy (COT) for chronic non-cancer pain increased dramatically over the past two decades.[34-36] Concurrently, opioid analgesic overdose deaths, addiction, misuse and diversion have increased markedly.[20,37]

COT may provide modest, variable short-term pain relief for some patients with chronic pain. Long-term benefits of COT for chronic pain have not been established. Potential medical and behavioral harms of opioids are an important concern, particularly at higher dosage levels and in higher risk or medically complex patients. While COT at lower doses may be a useful treatment for some patients, it should only be considered for carefully evaluated, closely monitored patients when a cautious, structured and selective approach is employed, and clear benefits for pain and function are documented. COT always entails risks for patients, their families and the community, so vigilance and caution are essential.

The content printed in this guide has been distributed, uploaded to the web and/or endorsed by the following agencies and organizations:

- The American College of Medical Toxicology
- Group Health Research Institute
- Maimonides Medical Center
- New York State Office of Alcoholism and Substance Abuse Services
- SAMA Foundation
- The United States Centers for Disease Control and Prevention
- Washington State Industrial Insurance Medical Advisory Committee

Myths and Facts about
Chronic Opioid Therapy (COT)

Myth	Fact
Myth: COT for chronic pain is supported by strong evidence.	**Fact:** Evidence of long-term efficacy for chronic non-cancer pain (≥16 weeks) is limited,[1,2,3] and of low quality.[4,5] Opioids are effective for short-term pain management. But, for many patients with chronic pain, analgesic efficacy is not maintained over long time periods.[6]
Myth: Physical dependence only happens with high doses over long periods of time.	**Fact:** With daily opioid use, physical dependence and tolerance can develop in days or weeks.[7,8]
Myth: Patients who develop physical dependence on opioids can easily be tapered off.	**FACT:** Successfully tapering chronic pain patients from opioids can be difficult – even for patients who are motivated to discontinue opioid use.[33]
Myth: Addiction is rare in patients receiving medically prescribed COT.	**Fact:** Estimates vary. Between 4% and 26% of patients receiving COT have an opioid use disorder.[9-12] Among patients without an opioid use disorder, more than one in ten misuse opioids by: intentional over-sedation; concurrently using alcohol for pain relief; hoarding medications; increasing dose on their own; and borrowing opioids from friends.[9,15]
Myth: Addiction is the main risk to be concerned about when prescribing opioids.	**Fact:** Opioids have significant risks besides addiction and misuse.[18,19] These risks include respiratory depression and unintentional overdose death;[20,21] serious fractures from falls;[22,23] hypogonadism and other endocrine effects that can cause a spectrum of adverse effects;[24] increased pain sensitivity,[25] sleep-disordered breathing,[26] chronic constipation and serious fecal impaction,[27,28] and chronic dry mouth which can lead to tooth decay.[29]
Myth: Extended-release opioids are better than short-acting opioids for managing chronic pain.	**Fact:** Extended-release opioids have **not** been proven to be safer or more effective than short-acting opioids for managing chronic pain.[30]
Myth: Prescribing high-dose opioid therapy (≥120 mg morphine equivalents/day) is supported by strong evidence that benefits outweigh risks.	**Fact:** No randomized trials show long-term effectiveness of high opioid doses for chronic non-cancer pain. Many patients on high doses continue to have substantial pain and related dysfunction.[32] Higher doses come with increased risks for adverse events and side effects including overdose, fractures, hormonal changes, and increased pain sensitivity.[18-26]
Myth: Opioid overdoses only occur among drug abusers and patients who attempt suicide.	**Fact:** Patients using prescription opioids are at risk of unintentional overdose and death.[20] This risk increases with dose and when opioids are combined with other CNS depressants like benzodiazepines and alcohol.[21]
Myth: Dose escalation is the best response when patients experience decreased pain control.	**Fact:** When treating chronic pain, dose escalation has **not** been proven to reduce pain or increase function, but it can increase risks.[32]

Do's & Don'ts for
Acute Pain Management

DO explain that opioids are for time-limited use. With the first opioid prescription, set expectations that opioids should be discontinued when the pain problem is no longer acute.

DON'T stock your patients' medicine cabinets with unused opioids. Limit all initial and refill prescriptions for acute pain. A 30-day supply is often excessive – many patients only take a pill or two then leave the rest in their medicine cabinet. This increases the risk of diversion, which in turn increases the risk of addiction and fatal overdose in families and communities. For those patients who use the medicine daily for several weeks, physiologic dependence develops within days or weeks. Due to risks of accidental poisoning, it is important to store opioids in a medication lock box and flush unused opioids down a sink or toilet.

DON'T start long-term use of opioids by accident. Long-term opioid prescribing should only occur after careful patient evaluation, discussion of risks and realistic expectations of benefits, and clear explanation of rules for safe use. Routine authorization of refills may cause patients to expect the prescription to continue indefinitely.

DON'T prescribe extended-release opioids for acute pain or to opioid-naïve patients. Extended-release opioids are not appropriate for managing acute pain and should never be prescribed to an opioid-naïve patient.

Do's & Don'ts for Chronic Pain Management

DON'T initiate chronic opioid therapy (COT) before considering safer alternatives such as primary disease management, cognitive-behavioral therapy (CBT), participating in pleasant and rewarding life activities, physical therapy, non-opioid analgesics and exercise.

DO screen patients for depression and other psychiatric disorders before initiating COT. Patients with depression and other mental health problems often present with pain problems. They may not know that mental health problems can contribute to chronic pain. These patients are at higher risk of opioid addiction. They may be better served by mental health treatment.

DO talk with patients about therapeutic goals, opioid risks, realistic benefits, and prescribing ground rules. Therapeutic goals should include increased activity and improved quality of life, not just pain relief. Patients should understand the full range of opioid risks and the limited benefits they can reasonably expect. The rules for safe and appropriate use of opioids need to be explicit, preferably documented in a written treatment agreement.

DO realize that patients are reluctant to disclose a history of substance abuse. A history of substance abuse indicates greater risk of opioid addiction, but getting an accurate picture of past and current drug use can be difficult. If a patient denies past or current substance abuse, recognize that they may be afraid to tell you the truth. Consult the medical record, a prescription drug monitoring database, and third parties as needed.

DO perform a thorough medical evaluation and a urine drug screen before initiating COT. Starting chronic opioid therapy should be an affirmative decision based on adequate assessment of risk, urine drug screening, and use of a treatment agreement. Because it can be difficult to know if a patient is seeking opioids for addiction or diversion purposes, COT should only be considered by a physician who has an ongoing relationship with the patient. The prescribing physician should be willing to continue working with the patient if problems arise.

DO explain to patients that discontinuing opioids may be difficult. Some patients find it difficult to taper off of opioids, particularly from higher dose regimens, even when they are eager to do so. Patients can experience increased pain, insomnia, or anxiety when tapering from opioids. These unpleasant withdrawal symptoms can last for several weeks. Do not abandon chronic pain patients after discontinuing opioids.

DO perform random urine drug screens on patients receiving COT. Urine drug screening helps identify patients using illicit drugs or not taking the medicine as prescribed.

DON'T continue COT with patients who show no progress toward treatment goals defined by increased function and reduced pain.

DON'T assume patients know how to use opioids safely. Opioids are powerful drugs that patients sometimes use in unsafe ways. Risks of unsafe use increase with prescribed dose and are greater for extended-release medications with long half-life. Patients often do not understand that it can be unsafe to take extended-release opioids "as-needed for pain." Take time to talk with patients about how they are using opioids. Ask patients about their problems and concerns.[17]

DON'T assume patients use opioids as you intend. Many patients vary their dose and use combinations of other CNS depressant drugs or alcohol in ways that you may not know about. Patients may also sell their medications or share them with others. Opioid misuse often occurs among patients who do not have an opioid use disorder.[9,15] Vigilance for unsafe use is essential.

DON'T start a treatment that you are not prepared to stop. Don't initiate COT without benchmarks for stopping, a procedure for tapering that you are willing and able to use, and an approach to managing physical and psychological withdrawal symptoms. If substance abuse is identified, taper opioids and make arrangements for substance abuse treatment.

DON'T assume patients are doing well with COT without careful evaluation. Careful and compassionate interviewing about opioid use and misuse, questions about your patients' problems and concerns,[17] screening questionnaires, urine drug screening, and information from prescription drug monitoring databases often reveal problems with prescription opioids that would otherwise be missed.

DON'T abandon patients with a prescription drug problem. For patients who are misusing or addicted to prescription opioids, offer help or referral to someone who can treat substance abuse.

Contributors

Physicians/Scientists:
Andrew Kolodny, MD
Gary Franklin, MD, MPH
Stephen Gelfand, MD
Petros Levounis, MD, MA
Rosemary Orr, MD

Len Paulozzi, MD, MPH
Jon Streltzer, MD
Art Van Zee, MD
Michael Von Korff, ScD

Patient/Family Advocates:
Peter Jackson
Betts Tully

External Reviewers:
Jane Ballantyne, MD
Roger Chou, MD
Mark Edlund, MD, PhD
Richard A. Deyo, MD, MPH   Mark Sullivan, MD, PhD
Thomas Kosten, MD   Judith Turner, PhD

For additional information, please contact Physicians for Responsible Opioid Prescribing:
Andrew Kolodny, MD, akolodny@maimonidesmed.org or Michael Von Korff, ScD, vonkorff.m@ghc.org

References

1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. *Pain* 2004;112:372-80.

2. Papaleontiou M, Henderson CR, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, Reid MC. Outcomes associated with opioid use in the treatment of chronic non-cancer pain in older adults: A systematic review and meta-analysis. *JAGS* 2010; 58:1353-1369.

3. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. *Ann Intern Med* 2007; 146:116-27.

4. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society – American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain. *J Pain* 2009; 10:113-130.

5. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological Management of Persistent Pain in Older Persons. *JAGS* 2009; 57:1331–1346, 2009.

6. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. *Clin J Pain* 2008; 24:469-78.

7. McQuay H. Opioids in pain management. *Lancet* 1999; 353: 2229-2232.

8. Baily CP and Connor M. Opioids: Cellular mechanisms of tolerance and physical dependence. *Current Opinion in Pharmacology* 2005; 5:60-80.

9. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance Use Disorders in a Primary Care Sample Receiving Daily Opioid Therapy. *J Pain* 2007; 8:573-582.

10. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Measurement of opioid problems among chronic pain patients in a general medical population. *Drug and Alcohol Dependence* 2009; 104:43-49.

11. Becker WC, Fiellin DA, Gallagher RM, Barth KS, Ross JT, Oslin DW. The association between chronic pain and prescription drug abuse in Veterans. *Pain Medicine* 2009; 10:531-536.

12. Boscarino JA, Rutstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart WF. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. *Addiction* 2010; 105:1776-1782.

13. Manchikanti L., Fellows B., Damron K.S., Pampati V., McManus C.D. Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: an evaluation of patterns and trends. *J Ky Med Assoc* 2005; 103: 55-62.

14. Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilliday BB, DeWalt DA, Pignone MP. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Services Research 2006; 6:46-55.

15. Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain – Development of a typology of chronic pain patients. *Drug and Alcohol Dependence* 2009; 104:34-42.

16. Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond Abuse and Exposure: Framing the Impact of Prescription-Medication Sharing. *Am J Public Health* 2008; 98:1115–1121.

17. Sullivan MD, Von Korff M, Banta-Green C, Merrill JA, Saunders K. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. *Pain* 2010; 149:345-353.

18. Ballantyne JC, Mao J. Opioid therapy for chronic pain. *N Engl J Med* 2003; 349:1943-53.

19. Von Korff M. Commentary on Boscarino et al. (2010): Understanding the spectrum of opioid abuse, misuse and harms among chronic opioid therapy patients. *Addiction* 2010; 105:1783-1784.

20. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. *Am J Prev Med* 2006; 31:506-11.

21. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. *Annals of Internal Medicine* 2010; 152:85-92.

22. Saunders KW, Dunn KM, Merrill JO, Sullivan MD, Weisner CM, Braden JB, Psaty BM, Von Korff M. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *Journal of General Internal Medicine* 2010; 25:310-315.

23. Takkouche B, Montes-Martinez A, Gill S, Etminan M. Psychotropic medications and the risk of fracture. *Drug Safety* 2007; 30(2):171-84.

24. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. *Endocr Rev* 2010; 31:98-132.

25. Zhou HY, Chen SR, Chen H, Pan HL. Opioid-induced long-term potentiation in the spinal cord is a presynaptic event. *Neuroscience* 2010; 30:4460-4466.

26. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, Shilling KC, Chronic Opioid Use is a Risk Factor for the Development of Central Sleep Apnea and Ataxic Breathing. *J Clin Sleep Medicine* 2007; 3:455-461.

27. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. *Neurogastroenterol Motil* 2010; 22:424-30.

28. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). *Pain Medicine* 2009; 10:35-42.

29. Murray Thomson W, Poulton R, Mark Broadbent J, Al-Kubaisy S: Xerostomia and medications among 32-year olds. *Acta Odontol Scand* 64:249-254, 2006

30. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. *J Pain Symptom Manage* 2003; 26:1026-1048.

31. Lusher J, Elander J, Bevan D, Telfer P, Burton B: Analgesic addiction and pseudoaddiction in painful chronic illness. *Clin J Pain* 2006; 22:316–324.

32. Franklin GM, Rahman EA, Turner JA, Daniell WA, Fulton-Kehoe D. Opioid use for chronic low back pain. A prospective, population-based study among injured workers in Washington State, 2002-2005. *Clin J Pain* 2009; 25:743-751.

33. Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. *J Addict Med* 2010; 4:140-146.

34. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. *Pain* 2004; 109(3):514-519.

35. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. *Pharmacoepidemiol Drug Saf* 2009; 18(12):1166-1175.

36. Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. *Pain* 2008; 138(2):440-449.

37. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and alcohol dependence 2003; 69:215-232.

POLICY IMPACT { PRESCRIPTION PAINKILLER OVERDOSES

CDC

WHAT'S THE ISSUE?

In a period of nine months, a tiny Kentucky county of fewer than 12,000 people sees a 53-year-old mother, her 35-year-old son, and seven others die by overdosing on pain medications obtained from pain clinics in Florida.[1] In Utah, a 13-year-old fatally overdoses on oxycodone pills taken from a friend's grandmother.[2] A 20-year-old Boston man dies from an overdose of methadone, only a year after his friend also died from a prescription drug overdose.[3]

These are not isolated events. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher. In 2008, more than 36,000 people died from drug overdoses, and most of these deaths were caused by prescription drugs.[4]

{100} One hundred people die from drug overdoses every day in the United States.[4]

Drug overdose death rates in the US have **more than tripled** since 1990.[5]

Death rate per 100,000 population*

12
10
8
6
4
2

1990   1992   1994   1996   1998   2000   2002   2004   2006   2008

*Deaths are those for which poisoning by drugs (illicit, prescription, and over-the-counter) was the underlying cause.

WHAT DO WE KNOW?

**The role of prescription painkillers**

Although many types of prescription drugs are abused, there is currently a growing, deadly epidemic of prescription painkiller abuse. Nearly three out of four prescription drug overdoses are caused by prescription painkillers—also called opioid pain relievers. The unprecedented rise in overdose deaths in the US parallels a 300% increase since 1999 in the sale of these strong painkillers.[4] These drugs were involved in 14,800 overdose deaths in 2008, more than cocaine and heroin combined.[4]

The misuse and abuse of prescription painkillers was responsible for more than 475,000 emergency department visits in 2009, a number that nearly doubled in just five years.[6]

More than 12 million people reported using prescription painkillers nonmedically in 2010, that is, using them without a prescription or for the feeling they cause.[7]

The role of alcohol and other drugs

About one-half of prescription painkiller deaths involve at least one other drug, including benzodiazepines, cocaine, and heroin. Alcohol is also involved in many overdose deaths.[8]

Commonly Abused Medications

Opioids
Derived from the opium poppy (or synthetic versions of it) and used for pain relief. Examples include hydrocodone (Vicodin®), oxycodone (OxyContin®, Percocet®), fentanyl (Duragesic®, Fentora®), methadone, and codeine.

Benzodiazepines
Central nervous system depressants used as sedatives, to induce sleep, prevent seizures, and relieve anxiety. Examples include alprazolam (Xanax®), diazepam (Valium®), and lorazepam (Ativan®).

Amphetamine-like drugs
Central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD). Examples include dextroamphetamine/amphetamine (Adderall®, Adderall XR®), and methylphenidate (Ritalin®, Concerta®).

In 2008, there were **14,800** prescription painkiller deaths.[4]

For every **1** death there are...

10 treatment admissions for abuse[9]

32 emergency dept visits for misuse or abuse[6]

130 people who abuse or are dependent[7]

825 nonmedical users[7]

How prescription painkiller deaths occur

Prescription painkillers work by binding to receptors in the brain to decrease the perception of pain. These powerful drugs can create a feeling of euphoria, cause physical dependence, and, in some people, lead to addiction. Prescription painkillers also cause sedation and slow down a person's breathing.

A person who is abusing prescription painkillers might take larger doses to achieve a euphoric effect and reduce withdrawal symptoms. These larger doses can cause breathing to slow down so much that breathing stops, resulting in a fatal overdose.

{ In 2010, 2 million people reported using prescription painkillers nonmedically for the first time within the last year—nearly 5,500 a day.[7] }

Where the drugs come from

Almost all prescription drugs involved in overdoses come from prescriptions originally; very few come from pharmacy theft. However, once they are prescribed and dispensed, prescription drugs are frequently diverted to people using them without prescriptions. More than three out of four people who misuse prescription painkillers use drugs prescribed to someone else.[7]

Most prescription painkillers are prescribed by primary care and internal medicine doctors and dentists, not specialists.[10] Roughly 20% of prescribers prescribe 80% of all prescription painkillers.[11, 12,13]

People who abuse prescription painkillers get drugs from a variety of sources[7]

Other source **7.1%**

Got from drug dealer or stranger **4.4%**

Took from friend or relative without asking **4.8%**

Bought from friend or relative **11.4%**

Prescribed by one doctor **17.3%**

Obtained free from friend or relative **55%**

Who is most at risk

Understanding the groups at highest risk for overdose can help states target interventions. Research shows that some groups are particularly vulnerable to prescription painkiller overdose:

- People who obtain multiple controlled substance prescriptions from multiple providers—a practice known as "doctor shopping."[14,15]

- People who take high daily dosages of prescription painkillers and those who misuse multiple abuse-prone prescription drugs.[15,16,17,18,19]

- Low-income people and those living in rural areas.

  - People on Medicaid are prescribed painkillers at twice the rate of non-Medicaid patients and are at six times the risk of prescription painkillers overdose.[20,21] One Washington State study found that 45% of people who died from prescription painkiller overdoses were Medicaid enrollees.[20]

- People with mental illness and those with a history of substance abuse.[19]

Where overdose deaths are the highest

The drug overdose epidemic is most severe in the Southwest and Appalachian region, and rates vary substantially between states. The highest drug overdose death rates in 2008 were found in New Mexico and West Virginia, which had rates nearly five times that of the state with the lowest rate, Nebraska.[4]

Drug overdose death rates by state, 2008[4]

NH	9.3
VT	10.9
MA	11.8
RI	17.2
CT	10.8
NJ	8
DE	14.5
MD	11.9
DC	9.4

14.7
14.1
7.6
7.2
12.3
11.7
9.7
7.3
10.5
8.4
14.4
5.5
7.1
12.2
10.5
19.6
18.4
14.6
8
13.2
15.1
15
10.4
10.5
13.1
25.8
13.1
17.9
9.1
13.1
27
15.8
14.8
12.9
13.1
12.6
10.6
13.1
9.5
8.6
15
16.5
18.1
9.4

Age-adjusted rate per 100,000

	5.5 - 9.4
	9.5 - 12.3
	12.4 - 14.8
	14.9 - 27.0

WHAT CAN WE DO?

There are many different points of intervention to prevent prescription drug overdoses. States play a central role in protecting the public health and regulating health care and the practice of the health professions. As such, states are especially critical to reversing the prescription drug overdose epidemic.

The following state policies show promise in reducing prescription drug abuse while ensuring patients have access to safe, effective pain treatment.

{ **Thirty-six states have operational PDMPs.**[22] }

CDC RECOMMENDATIONS

Prescription Drug Monitoring Programs
Prescription Drug Monitoring Programs (PDMPs) are state-run electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients. They are designed to monitor this information for suspected abuse or diversion—that is, the channeling of the drug into an illegal use—and can give a prescriber or pharmacist critical information regarding a patient's controlled substance prescription history. This information can help prescribers and pharmacists identify high-risk patients who would benefit from early interventions.

CDC recommends that PDMPs focus their resources on
* **patients** at highest risk in terms of prescription painkiller dosage, numbers of controlled substance prescriptions, and numbers of prescribers; and
* **prescribers** who clearly deviate from accepted medical practice in terms of prescription painkiller dosage, numbers of prescriptions for controlled substances, and proportion of doctor shoppers among their patients.

CDC also recommends that PDMPs link to electronic health records systems so that PDMP information is better integrated into health care providers' day-to-day practices.

Patient review and restriction programs

State benefits programs (like Medicaid) and workers' compensation programs should consider monitoring prescription claims information and PDMP data (where applicable) for signs of inappropriate use of controlled prescription drugs. For patients whose use of multiple providers cannot be justified on medical grounds, such programs should consider reimbursing claims for controlled prescription drugs from a single designated physician and a single designated pharmacy. This can improve the coordination of care and use of medical services, as well as ensure appropriate access, for patients who are at high risk for overdose.

Health care provider accountability

States should ensure that providers follow evidence-based guidelines for the safe and effective use of prescription painkillers. Swift regulatory action taken against health care providers acting outside the limits of accepted medical practice can decrease provider behaviors that contribute to prescription painkiller abuse, diversion, and overdose.

Laws to prevent prescription drug abuse and diversion

States can enact and enforce laws to prevent doctor shopping, the operation of rogue pain clinics or "pill mills," and other laws to reduce prescription painkiller diversion and abuse while safeguarding legitimate access to pain management services. These laws should also be rigorously evaluated for their effectiveness.

Better access to substance abuse treatment

Effective, accessible substance abuse treatment programs could reduce overdose among people struggling with dependence and addiction. States should increase access to these important programs.

These recommendations are based on promising interventions and expert opinion. Additional research is needed to understand the impact of these interventions on reducing prescription drug overdose deaths.

The amount of prescription painkillers sold in states varies[4]

The quantity of prescription painkillers sold to pharmacies, hospitals, and doctors' offices was 4 times larger in 2010 than in 1999. Enough prescription painkillers were prescribed in 2010 to medicate every American adult around-the-clock for one month.

Kilograms of prescription painkillers sold, rates per 10,000 people

3.7 - 5.9   6.0 - 7.2   7.3 - 8.4   8.5 - 12.6

POLICY IMPACT {

Policy Impact is a series of issue briefs from CDC's Injury Center highlighting key public health issues and important, science-based policy actions that can be taken to address them.

For more information on Prescription Drug Overdose, contact the Centers for Disease Control and Prevention:
www.cdc.gov/injury • cdcinfo@cdc.gov • 1-800-CDC-INFO (232-4636) | TTY 1-888-232-6348

November 2011

For references, visit: www.cdc.gov/homeandrecreationalsafety/rxbrief

ASIPP - Opioid Guidelines 2012

American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 - Guidance

Laxmaiah Manchikanti, MD[1], Salahadin Abdi, MD, PhD[2], Sairam Atluri, MD[3], Carl C. Balog, MD[4], Ramsin M. Benyamin, MD[5], Mark V. Boswell, MD, PhD[6], Keith R. Brown, PharmD[7], Brian M. Bruel, MD[8], David A. Bryce, MD[9], Patricia A. Burks, LPT[10], Allen W. Burton, MD[11], Aaron K. Calodney, MD[12], David L. Caraway, MD[13], Kimberly A. Cash, RT[14], Paul J. Christo, MD[15], Kim S. Damron, RN[16], Sukdeb Datta, MD[17], Timothy R. Deer, MD[18], Sudhir Diwan, MD[19], Ike Eriator, MD[20], Frank J.E. Falco, MD[21], Bert Fellows, MA[22], Stephanie Geffert, MLIS[23], Christopher G. Gharibo, MD[24], Scott E. Glaser, MD[25], Jay S. Grider, DO, PhD[26], Haroon Hameed, MD[27], Mariam Hameed, MD[28], Hans Hansen, MD[29], Michael E. Harned, MD[30], Salim M. Hayek, MD, PhD[31], Standiford Helm II, MD[32], Joshua A. Hirsch, MD[33], Jeffrey W. Janata, PhD[34], Adam M. Kaye, PharmD[35], Alan D. Kaye, MD, PhD[36], David S. Kloth, MD[37], Dhanalakshmi Koyyalagunta, MD[38], Marion Lee, MD[39], Yogesh Malla, MD[40], Kavita N. Manchikanti, MD[41], Carla D. McManus, RN, BSN[42], Vidyasagar Pampati, MSc[43], Allan T. Parr, MD[44], Ramarao Pasupuleti, MD[45], Vikram B. Patel, MD[46], Nalini Sehgal, MD[47], Sanford M. Silverman, MD[48], Vijay Singh, MD[49], Howard S. Smith, MD[50], Lee T. Snook, MD[51], Daneshvari R. Solanki, MD[52], Deborah H. Tracy, MD[53], Ricardo Vallejo, MD, PhD[54], Bradley W. Wargo, DO[55]

Results:

Part 2 of the guidelines on responsible opioid prescribing provides the following recommendations for initiating and maintaining chronic opioid therapy of 90 days or longer.

1. A) Comprehensive assessment and documentation is recommended before initiating opioid therapy, including documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (Evidence: good)

    B) Despite limited evidence for reliability and accuracy, screening for opioid use is recommended, as it will identify opioid abusers and reduce opioid abuse. (Evidence: limited)

    C) Prescription monitoring programs must be implemented, as they provide data on patterns of prescription usage, reduce prescription drug abuse or doctor shopping. (Evidence: good to fair)

    D) Urine drug testing (UDT) must be implemented from initiation along with subsequent adherence monitoring to decrease prescription drug abuse or illicit drug use when patients are in chronic pain management therapy. (Evidence: good)

2. A) Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (Evidence: good)

    B) Caution must be exercised in ordering various imaging and other evaluations, interpretation and communication with the patient; to avoid increased fear, activity restriction, requests for increased opioids, and maladaptive behaviors. (Evidence: good)

    C) Stratify patients into one of the 3 risk categories – low, medium, or high risk.

    D) A pain management consultation, may assist non-pain physicians, if high-dose opioid therapy is utilized. (Evidence: fair)

3. Essential to establish medical necessity prior to initiation or maintenance of opioid therapy. (Evidence: good)

4. Establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: good)

5. A) Long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting or moderate doses of long-acting opioids, as there is no significant difference between long-acting and short-acting opioids for their effectiveness or adverse effects. (Evidence: fair)

    B) The relative and absolute contraindications to opioid use in chronic non-cancer pain must be evaluated including respiratory instability, acute psychiatric instability, uncontrolled suicide risk, active or history of alcohol or substance abuse, confirmed allergy to opioid agents,

      coadministration of drugs capable of inducing life-limiting drug interaction, concomitant use of benzodiazepines, active diversion of controlled substances, and concomitant use of heavy doses of central nervous system depressants. (Evidence: fair to limited)

6.   A robust agreement which is followed by all parties is essential in initiating and maintaining opioid therapy as such agreements reduce overuse, misuse, abuse, and diversion. (Evidence: fair)

7.   A)   Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs with appropriate monitoring to provide effective relief and avoid side effects. (Evidence: fair for short-term effectiveness, limited for long-term effectiveness)

        B)   Up to 40 mg of morphine equivalent is considered as low dose, 41 to 90 mg of morphine equivalent as a moderate dose, and greater than 91 mg of morphine equivalence as high dose. (Evidence: fair)

        C)   In reference to long-acting opioids, titration must be carried out with caution and overdose and misuse must be avoided. (Evidence: good)

8.   A)   Methadone is recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (Evidence: limited)

        B)   Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days and yearly thereafter. (Evidence: fair)

9.   In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT and PMDPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (Evidence: fair)

10. Constipation must be closely monitored and a bowel regimen be initiated as soon as deemed necessary. (Evidence: good)

11. Chronic opioid therapy may be continued, with continuous adherence monitoring, in well-selected populations, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects. (Evidence: fair)

Disclaimer: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a "standard of care."

Key words: Chronic pain, persistent pain, non-cancer pain, controlled substances, substance abuse, prescription drug abuse, dependency, opioids, prescription monitoring, drug testing, adherence monitoring, diversion

Pain Physician 2012; 15:S67-S116

Evidence-based clinical practice guidelines for responsible opioid prescribing in non-cancer pain are statements developed to improve the quality of care, patient access, treatment outcomes, appropriateness of care, deficiency and effectiveness, and achieve cost containment by improving the cost-benefit ratio. The objectives of these guidelines are to provide clear and concise guidelines to physicians to improve patient access and to avoid diversion and abuse. Part 1 of these guidelines describes evidence assessment (1), whereas Part 2 of these guidelines - the present manuscript, describes guidance for responsible opioid prescribing.

The global epidemic of chronic pain with its related disability and opioid use and its related fatalities, are the predominant issues of concern in modern medicine, specifically in the United States (2-40). The escalating use of therapeutic opioids in the United States is correlated to an increase in the supply of opioids, from 96 mg of morphine equivalence per person in the United States in 1997 to 710 mg per person in 2010 (34,41). This is equivalent to 7.1 kg of opioid medication per 10,000 population or enough to supply every adult American with 5 mg of hydrocodone every 6 hours for 45 days. Sales have increased 280% for hydrocodone, 1,293% for methadone, and 866% for oxycodone from 1997 to 2007 (31), with the estimated number of prescriptions filled for opioids exceeding 256 million in the United States in 2009 (42-44). From 2006 to 2011, hydrocodone was the number one prescription in the United States (45). In 2007, based on a study by the International Narcotics Control Board (46), American's, constituting 4.6% of the global population, accounted for over 99% of the global consumption of hydrocodone and 83% of the global consumption of oxycodone,.

The explosive use of therapeutic opioids, however, is accompanied by increasing fatalities and adverse consequences, and a lack of evidence regarding long-term effectiveness and safety in the treatment of chronic non-cancer pain (46-115). Even the Institute of Medicine (IOM) report, considered a blueprint for transforming prevention, care, education, and research on

Vol. II Page 224

chronic pain recognizes the serious problem of diversion and abuse of opioid drugs and has questions about their long-term usefulness, all the while maintaining that effective pain management is a moral imperative, a professional responsibility, and the duty of the people in the healing professions (4,47). Coinciding with the liberalization of laws governing opioid prescribing for the treatment of chronic non-cancer pain by the state medical boards in the late 1990s, opioid prescriptions have seen dramatic increases for non-cancer pain over the past 2 decades (116). In addition, the introduction of new pain management standards for inpatient and outpatient medical care implemented by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) in 2000 (117), multiple physicians and advocacy organizations promoting increased use of opioids in the treatment of chronic non-cancer pain, the introduction of long-acting opioids with aggressive marketing by the pharmaceutical industry, and a growing awareness of right to pain relief, empowered by JCAHO standards, have fueled the explosion in opioid use, at least in the United Sates (118-121). It has been alleged, however, that these positions are largely based on poor science and misinformation in relation to the safety and effectiveness of opioids when prescribed by a physician and taken appropriately (51,60,62-65,118-132).

Opioid use for non-therapeutic purposes and also for chronic pain has increased over the years (63,66-68,70,76-79,85,106,127-176). It has been shown that 90% of patients present to pain management settings with prior opioid therapy, with a similar number of patients on opioids in treatment (159-174). Further, Deyo et al (30) illustrated that approximately 61% of patients with low back pain in primary care settings were on a course of opioids and that of these, 19% were long-term users. Multiple surveys have illustrated that the majority of prescriptions are from primary specialties, followed by surgical specialties rather than pain physicians (42-45). As shown in Figure 1, 42% of immediate release opioids and 44% of long-acting opioids were prescribed by primary care physicians, whereas specialties identified as pain management, including anesthesiology and PMR, contributed to 6% of immediate release opioids and 23% of long-acting opioids (42-45).

Multiple guidelines have been published with advice for long-term opioid therapy in chronic non-cancer pain. Stein et al (59) assessed recently published guidelines, which included the guidelines by the American Pain Society (APS)-American Academy of Pain Medicine (AAPM) guidelines (50), British Pain Society's guidelines (52), Canadian National Opioid Use Guideline Group (NOUGG) (54), German guidelines (49), and guidelines

Fig. 1. *Total number of prescriptions dispensed in the U.S. by various specialties for IR and ER/LA opioids in 2009*

Vol. II Page 225

by the American Society of Interventional Pain Physicians (55). It should be noted that this document serves, in part, to update the American Society of Interventional Pain Physicians' guidelines. Sorgatz and Maier (57) summarized that the 5 guidelines impact assessment of opioids in chronic non-cancer pain only in diction. They stated the following:

♦ APS-AAPM: "Although evidence is limited, an expert panel (...) concludes that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic non-cancer pain. However, opioids are also associated with potentially serious harms (...) "(50).

♦ The British Pain Society guidelines state "There is evidence from clinical trials that opioids can be effective in the short and medium term (...) However, the safety and efficacy of opioids in the long-term is uncertain (...)" (52).

♦ The guidelines by American Society of Interventional Pain Physicians state: "Opioids are commonly prescribed for chronic non-cancer pain and may be effective for short-term pain relief. However, long-term effectiveness of 6 months or longer is variable ..." (55).

♦ The Canadian guidelines National Opioid Use Guideline Group (NOUGG) state that "opioids showed only small to moderate benefits for nociceptive (...) neuropathic (...) improving function and relieving pain" (58).

In APS-AAPM guidelines for the use of chronic opioid therapy in chronic non-cancer pain (50,51), despite scant evidence, the expert panel concluded that chronic opioid therapy could be effective therapy for carefully selected and monitored patients with chronic non-cancer pain. They provided recommendations and guidance on patient selection and risk stratification; informed consent and opioid management plans, initiation and titration of chronic opioid therapy, use of methadone, monitoring of patients on chronic opioid therapy, dose escalations, high-dose therapy, opioid rotation, and indications for discontinuation of therapy, prevention and management of opioid-related adverse effects, driving and work safety, identifying a medical home and when to obtain consultation, management of breakthrough pain, chronic opioid therapy in pregnancy and opioid-related policies.

Canadian Guidelines (54) for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain have analyzed the evidence and have provided recommendations with

5 clusters. Cluster 1 dealt with deciding to initiate opioid therapy with comprehensive assessment, addiction-risk screening, urine drug screening, opioid efficacy, risks, adverse effects, complications, and benzodiazepine tapering. Cluster 2 dealt with conducting an opioid trial with titration and driving, stepped opioid selection, optimal dose, watchful dose, and opioid misuse. Cluster 3 described monitoring of long-term opioid therapy with monitoring, switching or discontinuing opioids, impact on driving, revisiting opioid trial steps, and collaborative care. Cluster 4 described treating specific populations with long-term opioid therapy including the elderly, adolescents, pregnant patients, and patients suffering with comorbid psychiatric conditions. Finally, Cluster 5 described managing opioid misuse and addiction with addiction treatment options, prescription fraud, unacceptable patient behavior, and acute care opioid prescribing policies.

The British Pain Society's Opioids for Persistent Pain (52) described the pharmacology of opioids, necessity to prescribe opioids, adverse effects of opioid therapy, practical aspects of prescribing, non-medical prescriptions of opioids, and opioids and problem drug use.

Hughes et al (177) also performed a systematic review of treatment guidelines, published in 2011. They included 6 clinical guidelines meeting inclusion criteria with one duplicate (50,54,55,58,178-180). Three of the guidelines, including Canadian guidelines and APS-AAPM guidelines were included by Stein et al (59), whereas 3 other guidelines were not included by Stein et al (178-180). Hughes et al (177) concluded that since evidence supporting efficacy for the use of opioids as treatment for chronic non-cancer pain was limited, opioids for chronic non-cancer pain should be reserved for select patients with moderate or severe pain that significantly affects function or quality of life. They also concluded that continuation of opioid therapy is indicated if documentation supports the opioid results in improvement in those limitations. Furthermore, their recommendations included a comprehensive pre-treatment assessment, identification of contraindications, obtaining informed consent, establishing a written treatment plan with goals and objectives, using an opioid treatment agreement, obtaining specialist referral when indicated, and establishing a follow-up plan that includes monitoring for adverse effects, titration and rotation of medication, prescription use monitoring, use of drug screening, and thorough record keeping which includes documentation of functional improvement.

However, the Interagency Guideline on Opioid

Vol. II Page 226

Dosing for Chronic Non-Cancer Pain (53), also provided guidance sponsored by the Washington State Agency Medical Directors Group (AMDG). This guideline is provided in 2 parts: Part 1 included guidance for initiation, transition, and maintenance of oral opioids for chronic non-cancer pain, and Part 2 describes guidance for optimizing treatment and when opioid doses are greater than 120 mg morphine equivalence per day.

Thus, in order to curtail opioid abuse but at the same time provide appropriate treatment for pain patients, the focus must be on misuse, abuse, and diversion, and should be addressed in 4 fronts: education, establishing medical necessity, supply, and drugs. These guidelines have been prepared with these aspects as the primary focus and with consideration of up-to-date literature, with special attention being given to the effectiveness of opioids in long-term therapy in conjunction with adverse consequences. Chronic opioid therapy has been defined as daily or near-daily use of opioids for at least 90 days, often indefinitely (50).

In fact, Franklin et al (181) showed that this guidance is effective in bending prescription opioid dosing and reducing mortality. In this study, Franklin et al (181) showed a substantial decline in both the morphine equivalent dose per day of long-acting Schedule II opioids by 27% and the proportion of workers on doses equal to or greater than 120 mg per day of morphine equivalent dosage by 35%, compared prior to 2007. Further, there was also a 50% decrease from 2009 to 2010 in the number of deaths.

Opioid prescribing may be different for different specialities and settings based on the speciality and training. Consequently, additional modalities may be utilized instead of high dose opioid therapy, leading to low or moderate dose opioid therapy and avoiding multiple complications (182). These include various techniques of rehabilitation with therapeutic exercise programs, physical therapy, occupational therapy; cognitive behavioral therapy with psychological interventions, surgical interventions, or interventional techniques.

In interventional pain management, patients may receive not only opioid analgesics, but also other controlled or non-controlled drugs, to manage comorbid psychiatric and psychological disorders. Consequently, the effectiveness studies of opioids published thus far may not apply in the majority of interventional pain management patients. Indeed, in an interventional pain practice, controlled substances may be prescribed at lower doses, particularly opioid analgesics, in conjunction with interventional techniques (182). It has also been shown that interventional techniques may reduce psychological distress and improve functional status (183-201). More likely than not, the requirement for opioids and adjuvant drugs may be reduced or at least become stable. Hence, interventional pain physicians probably should not compare patients in their settings undergoing interventional techniques with others receiving drug therapy as mainstay treatment. Monotherapy, particularly with opioids, may be appropriate for only a small subgroup of those with chronic pain. Additionally, in interventional pain management, the majority of the patients are presented on opioid therapy and it is well understood that once patients are on opioids, they will not be weaned off of them regardless of reported improvements in pain relief and functional status.

The concept of "universal precautions," first seen in medicine with the explosion of HIV and hepatitis tainted blood, was introduced to counter the misconception that a provider would be able to predict "by looking" who might have a communicable blood-borne disease. This led to the use of "precautions" (gloves, etc.) for all patients, regardless of their age or socio-economic class. A rational approach to the treatment of chronic pain with opioids has been described using a pain and addiction continuum and a substance use assessment in a pain patient leading to the implementation of "universal precautions" in pain medicine (202).

The current guidelines manuscript focuses on responsible chronic opioid therapy, chronic opioid prescribing of 90 days or longer in chronic non-cancer pain, in order to improve quality of care, patient access, treatment outcomes, appropriateness of care, efficiency and effectiveness and achieve cost containment by improving the cost-benefit ratio. The objectives of these guidelines are to provide clear and concise guidelines to physicians, to improve patient access and to avoid diversion and abuse. Consequently, these guidelines are developed to be used by physicians practicing interventional pain management/pain medicine or other specialists involved in chronic opioid therapy. Thus, the focus of these guidelines and also for physicians dealing with chronic opioid therapy should be to curtail the abuse of opioids without jeopardizing non-cancer pain management. These guidelines only recommend proper use and do not recommend total elimination of opioids in managing chronic pain. Various principles of opioid use with appropriate evidence-based recommendations are illustrated in Figure 2 showing guid-

ance to opioid therapy. Since evidence supporting the efficacy for use of opioids as treatment of chronic non-cancer pain is limited and based on short-term studies, long-term opioid therapy for chronic non-cancer pain should be reserved for select patients with moderate or severe pain that significantly affects function or quality of life. In addition, continuation of opioid therapy is indicated if documentation supports the opioid results in

Patients with Chronic Non-Cancer Pain

INITIAL STEPS
- Comprehensive assessment
- Assessment of risk of misuse
- Screening tests (optional)
- Inquiry of prescription monitoring programs
- Baseline urine drug testing

DIAGNOSIS
- X-rays, MRI, CT, neurophysiologic studies
- Psychological evaluation (basic)
- Precision diagnostic interventions (optional)
- Consultation(s) as needed

MEDICAL NECESSITY
- Physical diagnosis
- Non-controlled substance therapy
- Physical modalities
- Behavioral interventions (optional)
- Interventional pain management (optional)
- Other alternatives
- Consultation(s) as needed

TREATMENT GOALS
- Decrease pain by 30% and/or increase function by 30%
- Minimal adverse effects

- Assess effectiveness of opioid therapy

INFORMED DECISION-MAKING
- Controlled substance agreement
- Random evaluations including pill counts and urine drug testing

INITIAL TREATMENT (8-12 WEEKS)
- Stratification of risk
- Understanding opioids
- Initiation with low dose short-acting opioid therapy
- Titrate

ADHERENCE MONITORING
- Prescription drug monitoring programs
- Urine drug testing (follow urine drug testing algorithm)
- Pill counts
- Behavioral assessment during each visit

SIDE EFFECTS
- Driving
- Sedation
- Constipation
- Breathing

DISCONTINUE
- Persistent or new pain
- Abuse, misuse
- Lack of analgesia
- Lack of activity
- Adverse effects
- Aberrant behavior

CONTINUE
- Analgesia of 30% and/or activity increase by 30%
- No misuse, abuse, adverse effects, manageable

- Taper and discontinue
- Repeat comprehensive evaluation
- Consider consultation

- Continue monitoring
- Wean, discharge, or maintain

Fig. 2. *Guidance to opioid therapy.*

Vol. II Page 228

improvement in pain and function. If opioid therapy is indicated, for initiation or continuation, recommendations in this document may be followed.

1.0 Initial Steps of Opioid Therapy

Before the initiation of opioid therapy it is essential that comprehensive assessment and documentation of the patient's physical condition, general medical condition, psychological history, psychiatric status, substance use and abuse history of the patient and family be obtained (50,52,53,55,58,177-180).

1.1 Comprehensive Assessment

1.1.1 Pain Condition

A thorough history and physical examination must be documented to determine the type, cause, and nature of the pain, including questions about past investigations and interventions for pain. This history also should include medication trials and the pain intensity and the functional impairment that arises from it (i.e., impact of pain on activities of daily living, work, and other aspects of life). In addition, various circumstances which increase or exacerbate the pain and conditions which lead to diminution of pain must be documented (203-206). A physical diagnosis must be established prior to initiating opioid therapy. The diagnosis should not be non-specific such as low back pain, knee pain etc., but should be objective and somewhat specific based on the type of pain and abnormalities identified. This will assist in future treatments based on whether the pain is nociceptive, neuropathic, somatic, radicular, widespread, or localized.

1.1.2 General Medical History

General medical history includes questions about general physical health, emotional health, and medication usage (203-206). Chronic pain patients tend to have multiple medical comorbid conditions which may increase the pain levels or may interact with multiple other drugs.

1.1.3 Psychosocial History

Psychosocial history includes information regarding their upbringing, family and social support, family obligations, work status, use of alcohol, smoking, and living arrangements.

1.1.4 Functional Status

A history of the functional status of a patient includes information about their ability to perform activities of daily living, work, play, and socialization. Assessment may be performed utilizing the Oswestry Disability Index, Neck Disability Index, or another measure.

1.1.5 Sleep Patterns

Sleeping is an important function, specifically in patients with generalized pain problems such as fibromyalgia and with the elderly.

1.1.6 Psychological Evaluation

Psychological evaluation may be performed with a simple evaluation for depression, anxiety, and somatization. Patients with major personality disorders need further evaluation and appropriate consultations (203-206).

Psychiatric status includes information regarding the patient's current and past history of psychiatric disorders and treatments and family history of psychiatric disorders.

1.1.7 Substance Use History

Substance use history includes multiple questions in reference to current, past, and family history of substance use, abuse, and addiction to alcohol, tobacco, prescription drugs, street drugs, illicit drugs, over-the-counter medications, solvents, etc. Furthermore, history in reference to attendance at a treatment program for addiction or treatment in an outpatient office detoxification etc., must be documented (203-206).

1.1.8 Addiction Risk Screening

Before initiating opioid therapy, a physician may consider using a screening tool to determine the patient's risk for opioid addiction. This evaluation is part of the comprehensive assessment. Comprehensive history also includes a thorough review of the patient's alcohol and other substance use. The history is important in assessing the patients risk for opioid misuse or addiction. Various screening tools may help with the determination. Most of the screening tools have not been studied in depth, validated, or been compared to each other. Thus, the evidence is poor as to their reliability (1,40,77-79,207-214).

1.1.9 Prescription Monitoring Programs

Before initiating therapy, a physician must obtain data from the prescription monitoring program. If a prescription monitoring program is not available, the physician must request information from all previous

physicians as well as pharmacies a patient uses or has used. While the evidence shows a general lack of reliability and accuracy for the multiple screening tools for opioid abuse, there is good evidence that prescription monitoring programs provide data on patterns of prescription usage, and fair evidence that prescription drug monitoring programs (PDMPs) can reduce prescription drug abuse or doctor shopping (1). However, the evidence that PDMPs reduce emergency room visits, drug overdoses, or deaths is poor. PDMPs collect statewide data about prescription drugs and track their flow (213,215-224). There are 3 components of these programs. The first component involves collecting data for prescriptions, documenting the physicians who wrote them and the pharmacies that dispensed them. With the enactment of the National All Schedules Electronic Reporting (NASPER) Act, physicians will have access to a database that has the capacity to monitor all transactions. In fact, some states are already mandating such use of prescription monitoring programs (221). To date, in the United States 38 states have functioning PDMPs, with 48 states with legislation passed (224), but there is a significant difference in the manner and frequency with which the data is collected.

1.1.10 Urine Drug Screening

In initiating and maintaining chronic opioid therapy, urine drug testing (UDT) must be used to establish a baseline measure of risk or to monitor compliance (40,51,54,149,172,173,207-213,225-234). However, it is essential to understand pharmacology, pharmacodynamics, drug interactions, and to have knowledge of interpretation and a plan in place to use the results, without financial considerations as the driving force (235-239).

UDT has been described in Part I and other manuscripts (40,53,54,225-231,237-240). Various details of interpretation of UDT are shown in Tables 1–3.

Physicians face multiple issues when utilizing UDT. In particular, the implication that the physician does not trust his or her patient. Information gained from UDT is limited regarding whether a patient is taking the dosages prescribed, or if they are a high metabolizer. UDT can reveal whether they are taking illicit substances.

♦ Drug screening should not imply that a physician does not trust the patients or that patients are not trustworthy. The literature, however, shows that self-reporting of drug use and behavioral monitor-

Table 1. *Urine drug testing: Typical screening and confirmation cut-off concentrations and detection times for drugs of abuse.*

Drug	Screening cut-off concentrations ng/mL urine	Confirmation cut-off concentrations ng/mL	Urine detection time	Immunoassay (I) Chromatography (C)
Hydrocodone	300	50	1–2 days	I & C
Oxycodone	100	50	1–3 days	I & C
Morphine	300	50	3–4 days	I & C
Methadone	300	100	5–10 days	I & C
Hydromorphone	300	100	1–2 days	I & C
Meperidine	300	100	1–2 days	I & C
Codeine	300	50	1–3 days	I & C
Benzodiazepines	200	20–50	Up to 30 days	I
Barbiturates	200	100	2–10 days	I & C
Marijuana	50	15	1–3 days for casual use; up to 11 weeks for chronic use	I & C
Cocaine	300	50	1–3 days	I & C
Amphetamine	1,000	100	2–4 days	I & C
Methamphetamine	1,000	100	2–4 days	I & C
Heroin*	10	25	1–3 days	I & C
Phencyclidine	25	10	2–8 days	I & C

*6-MAM, the specific metabolite is detected only for 6 hours.

Table 2. *Drug cross-reactants.*

Drug Group	Cross Reactivity Based on Product Insert	Cross Reactivity Based on Potential Cross-Reaction
Cannabinoids	Dronabinol (Marinol)	NSAIDs Efavirenz (Sustiva) Hemp Seed Oil (Cannabis seed) Pantoprazole (Protonix) Nexium Prilosec
Opioids	6-Acetylmorphine Ethyl morphine Oxymorphone Oxycodone Methadone Dextromethorphan	Fluoroquinolones Ofloxacin (Floxin) Papaverine Poppy Seeds Rifampicin & Rifampin (Rimactane, Rifadin, Rofact) Levofloxacin (Levaquin)
Amphetamines	Dextroamphetamine + amphetamine (Adderall)	Ephedrine Methylphenidate Trazodone Bupropion Desipramine Amantadine Ranitidine Phenylpropanolamine Vicks Vapor Spray Phentermine (Adipex/Obenix/Oby-Trim) Pseudoephedrine
Methamphetamine	d-Methamphetamine d-Amphetamine Chloroquine (Aralen) Desoxyephedrine MDMA (Ecstasy) Methamphetamine (Desoxyn)	Bupropion (Wellbutrin & Zyban) Chloroquine (Aralen) Chlorpromazine (Thorazine, Largactil) Desipramine (Norpramin) Dextroamphetamine (Dexedrine) Ephedrine (Ephedra and Ma Huang) Fenfluramine (Fen Phen) Labetalol (Labetalol) Mexiletine (Mexitil) n-acetyl procainamide (Procainamide) Phenylephrine (Neo-synephrine) Propranolol (Inderal) Pseudoephedrine (Claritin-D) Quinacrine (Atabrine, Mepacrine) Ranitidine (Zantac) Selegiline (Selegiline) Trazodone (Desyrel, Desyrel Dividose) Tyramine (Tyramine)
PCP	None	Chlorpromazine Meperidine Doxylamine Dextromethorphan Diphenhydramine (Benadryl) Thioridazine (Mellaril) Venlafaxine (Effexor)
Benzodiazepine	Bromazepam (Tenix) Clobazam (Mystan) Estazolam (ProSom)	Oxaprozin (Daypro) Sertraline (Zoloft) Some herbal agents
Cocaine	Benzoylecgonine Ecgonine Ecgonine Methyl Ester	TAC Solution (TAC Solution)
ETOH	None	Asthma inhalers (sometimes)
Methadone	None	Propoxyphene Seroquel

Vol. II Page 231

Table 2 (cont.). *Drug cross-reactants.*

Drug Group	Cross Reactivity Based on Product Insert	Cross Reactivity Based on Potential Cross-Reaction
Barbiturates	Alphenal	Phenytoin (Dilantin) Primidone (Mysoline)
Oxycodone	Hydrocodone Hydromorphone (Dilaudid) Oxymorphone (Numorphan) Codeine (Codeine)	

Source: DrugCheck® Cross Reactivity Chart (www.drugcheck.com/_images/DC145_Cross-Reactivity_chart.pdf)

Table 3. *Interpreting unexpected results of urine drug screens.*

	Unexpected Result	Possible Explanations	Actions for the Physician
1	UDS negative for prescribed opioid.	• False negative. • Non-compliance. • Diversion.	• Repeat test using chromatography; specify the drug of interest (e.g. oxycodone often missed by immunoassay). • Take a detailed history of the patient's medication use for the preceding 7 days (e.g., could learn that patient ran out several days prior to test). • Ask patient if they've given the drug to others. • Monitor compliance with pill counts.
2	UDS positive for non-prescribed opioid or benzodiazepines.	• False positive. • Patient acquired opioids from other sources (double doctoring, "street").	• Repeat UDS regularly. • Ask the patient if they accessed opioids from other sources. • Assess for opioid misuse/addiction. • Review/revise treatment agreement.
3	UDS positive for illicit drugs (e.g., cocaine, cannabis).	• False positive. • Patient is occasional user or addicted to the illicit drug. • Cannabis is positive for patients taking dronabinol (Marinol®), THC:CBD (Sativex®) or using medical marijuana.	• Repeat UDS regularly. • Assess for abuse/addiction and refer for addiction treatment as appropriate. • Ask about medical prescription of dronabinol, THC:CBD or medical marijuana access program.
4	Urine creatinine is lower than 2–3 mmol/liter.	• Patient added water to sample.	• Repeat UDS. • Consider supervised collection or temperature testing. • Take a detailed history of the patient's medication use for the preceding 7 days. • Review/revise treatment agreement.
5	Urine sample is cold.	• Delay in handling sample (urine cools within minutes). • Patient added water to sample.	• Repeat UDS, consider supervised collection or temperature testing. • Take a detailed history of the patient's medication use for the preceding 7 days. • Review/revise treatment agreement.

UDS=urine drug screen; THC=Tetrahydrocannabinol; CBD=cannabidiol

Source: Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain© 2010 National Opioid Use Guideline Group (NOUGG) (54).

ing fail to detect problems with drug misuse and abuse (53). Creating a UDT policy that is applicable universally and consistently with all patients assists to "de-stigmatize" UDT and can potentially convince patients that it has nothing to do with an individual patient or their trustworthiness (53,54). Consequently, the practice can explain to patients that drug testing is a routine procedure for all patients starting or maintained on opioid therapy and it is an important tool for monitoring the safety of opioid therapy. The UDT not only provides adherence monitoring, but it is also a monitoring tool for safety.

♦ As it is very difficult to correlate urine drug concentration with a patient's dose, it is not feasible for the physician to ascertain whether or not a patient has taken the dose of opioid appropriately using UDT. UDT can, however, detect the parent drug and/or its metabolites and demonstrate recent use of prescribed drugs and illegal substances. UDT will

not detect the amount of medication taken, when it was taken or identify the source of the drug.

♦ Some patients state that the expected drug is not found in the urine because they are high metabolizers. They may state that they are on diuretics and are drinking fluids to lose weight or on diet pills, and since they have so much fat, it cannot be detected. Most of the explanations are untrue, however, as only a small percentage of persons are considered ultra rapid metabolizers and may metabolize specific drugs more rapidly than typical patients (53). It would be rare for someone to take an opioid as prescribed and have a negative UDT. Moreover, diuretics, water intake, and excessive fat do not influence urine drug concentrations to an extent that one cannot influence urine drug concentrations. It is also crucial that the testing methodology used to identify the specific medication of interest have a low cut-off threshold. When possible, "no threshold" should be requested.

There is a misconception that short-acting opioids are not detected in the urine. In fact, most opioids are detectable in the body from one to 2 days. Short-acting opioids can be detected with no threshold testing.

♦ Confirmation of the results is a major issue. Proponents argue that each and every specimen must be sent to the lab and confirmed for a myriad of drugs; while others state that immunoassay testing is reliable and that confirmation should only be requested if there are questions with reference to results and patient history. If a patient admits that they have used a licit or illicit drug other than the prescriptions and if that drug is testing positive, there is no need to confirm this with laboratory testing. If, however, the patient denies any such use, it is essential that the result is confirmed through laboratory testing with LC/MS/MS. There is a significant correlation between immunoassay and chromatography for a majority of drugs (172,173). However, on occasion, it should be noted that even confirmatory testing requires expert assistance for interpretation (53). Most importantly with confirmation testing, while noting that financial incentives are put aside, understanding the pharmacology and metabolism of the drugs is essential.

♦ Some of the most common questions arise when dealing with marijuana. While for many people marijuana is a highly controversial and complex is-

sue, the Drug Enforcement Administration (DEA) currently classifies it as a Schedule I drug. For that reason, many providers do not prescribe opioids to patients using marijuana or give them one opportunity to stop using them. Other providers reference state "medical marijuana" laws (http://apps.leg.wa.gov/RCW/default.aspx?cite=69.51A&full=true) (53) and feel comfortable prescribing opioids to marijuana users. Some providers adopt a "don't ask, don't tell" policy, whereas others request the lab to remove marijuana from the UDT so that positive results are not seen. While this may be a risky practice, physicians should create their office policies and disclose them to patients. These policies, should, of course, follow all state and federal regulations apart from policies addressing personal ethics and beliefs.

1.2 Recommendations

1. Comprehensive assessment and documentation is recommended before initiating opioid therapy, including documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (Evidence: good)

2. Despite limited evidence for reliability and accuracy, screening for opioid use is recommended, as it will identify opioid abusers and reduce opioid abuse. (Evidence: limited)

3. Prescription monitoring programs must be implemented due to regulations, as they provide data on patterns of prescription usage, reduce prescription drug abuse or doctor shopping, and PDMPs may reduce emergency room visits, drug overdoses, or deaths. (Evidence: good to fair)

4. UDT must be implemented from initiation along with subsequent adherence monitoring, in an in-office setting with immunoassay and confirmation for accuracy with chromatography in select cases, to identify patients who are non-compliant or abusing prescription drugs or illicit drugs, and UDT may decrease prescription drug abuse or illicit drug use when patients are in chronic pain management therapy. (Evidence: good)

2.0 ESTABLISHING DIAGNOSIS

Diagnosis may be established by various means including physical examination, x-rays, magnetic resonance imaging (MRI), computed tomography (CT), and neurophysiologic studies. Furthermore, psychological

evaluations and precision diagnostic interventions may also be applied. Diagnostic interventional techniques will assist in making the proper diagnosis by following an algorithmic approach. Research shows that in approximately 70% to 85% of patients with spinal pain, an accurate diagnosis may not be provided even with the available history, physical examination, electromyographic (EMG)/nerve conduction studies, and radiologic evaluation (179,240-269). With precise diagnostic interventional techniques, the chances of an accurate diagnosis may be improved substantially, and proper treatment may be offered (270-273). Once the diagnosis is established, various modalities of therapy may be offered with interventional techniques or other techniques. Whatever opioids are required will be prescribed in low doses or eliminated.

Given the degree to which routine imaging has been criticized, it may be appropriate that physicians follow the recommendations provided by professional organizations and governmental organizations. In ordering various investigations, being conservative may be prudent, along with their interpretation, due to findings in asymptomatic patients and also the psychological factors and nocebo effect introduced in these patients with graphic description of asymptomatic abnormalities (252-292). Guidelines provided by specialty societies are appropriate if they were peer-reviewed and developed utilizing guidance from IOM criteria. Early imaging is discouraged in all circles. It is also crucial to realize that numerous abnormalities are generally found on imaging in asymptomatic subjects (262-292). In the era of information disclosure and electronic media, findings which do not correlate with symptoms and do not provide certainty as a pathological entity should be addressed by qualified physicians, not by technologists and radiologists, without any clinical correlation. Irrelevant and non-corroborative findings create fear and activity avoidance, resulting in negative consequences including requests for increased opioid dosages.

The role of neurophysiologic testing is limited in chronic pain management, even though some insurers mistakenly focus on the neurophysiologic evaluation and findings (252-256,275).

2.1 Consultation(s)

Physicians should be willing to refer a patient as clinically indicated for additional evaluation to achieve treatment objectives. Special attention should be given to those patients who are at risk of misusing their medications and those whose living arrangements create a risk for medication misuse or diversion. The management of patients with a history of substance abuse or with a coexisting psychiatric disorder may require extra care, monitoring, documentation, and consultation with, or referral to, an addictionologist. The lack of well-trained psychologists and psychiatrists in chronic pain management in many regions of the country may make this referral difficult to obtain. Likewise, in many locations there are no clinically trained addiction specialists with whom to collaborate.

Interagency guidelines on opioid dosing for chronic non-cancer pain (53) have proven to be effective in reducing opioid usage and deaths, and include thresholds for pain consultation. The hallmark of this guideline (53) is a recommendation not to prescribe more than an average daily morphine equivalent dose of 120 mg without either the patient demonstrating improvement in function and pain or first obtaining a consultation from a pain management expert. This concept was based on the results of a study by Dunn et al (135), which showed that patients receiving 100 mg or more per day morphine equivalent doses had a 9-fold increase in overdose risk with 12% fatal overdoses and most overdoses being medically serious. Furthermore, high-dose opioid therapy can be ineffective and/or unsafe (53). Higher strength opioids may be associated with poorer functional outcomes and adverse consequences (26,32,33,90,135,293-296).

2.2 Recommendations

1. Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (Evidence: good)
2. Caution must be exercised in ordering various imaging and other evaluations, and only appropriate information in the realm of clinical relevance shall be provided by the treating physician to the patients when there is correlation of the symptoms with findings; to avoid increased fear, activity restriction, requests for increased opioids, and maladaptive behaviors. (Evidence: good)
3. A pain management consultation, for non-pain physicians, if high-dose opioid therapy is being utilized. (Evidence: fair)

3.0 ESTABLISHING MEDICAL NECESSITY

To establish medical necessity for opioid therapy, it is essential to have a physical diagnosis and information of multiple modalities of treatments available including

conservative, various other alternatives, and consultations if necessary. These include non-controlled substance therapy, physical modalities, behavioral interventions, interventional pain management techniques, and any other alternatives.

Medical necessity is established only when the following criteria are met: pain of moderate to severe degree; suspected organic problem; documented failure to respond to non-controlled substance, adjuvant agents, physician ordered physical therapy, structured exercise program; and interventional techniques, specifically for long-term high-dose therapy.

Opioids may be used as a second-line treatment. For non-opioid controlled substance, appropriate documentation of psychological status must be documented.

Continued medical necessity depends on the following 4 "A's":
• Analgesia
• Activity
• Aberrant behavior
• Adverse effects

Behavioral interventions, interventional pain management, various other alternatives, and consultations as needed must be obtained.

3.1 Recommendations
It is essential to establish medical necessity prior to initiation or maintenance of opioid therapy. (Evidence: good)

4.0 Establishing Treatment Goals

It is essential to establish treatment goals. Treatment goals should combine pain relief with improvement in activity and minimal or no adverse effects. To achieve the treatment goals, outcomes assessment is essential. Outcomes may be assessed by numeric rating scale pain (0–10 scale), functional assessment using the Oswestry Disability Index (0–50 scale), Neck Disability Index (0–50 scale), employment status, and/or improvement in activity status. The minimum amount of change in pain score in order to be clinically meaningful has been described as a 2-point change on a scale of 0 to 10 (or 20 percentage points), based on findings in trials which have been commonly utilized studying general chronic pain (297), chronic musculoskeletal pain (298), and chronic low back pain (297-302). Consequently, for guideline purposes, it would be appropriate to use clinically meaningful pain relief of at least 30% and/or a 3-point change on an 11-point scale of 0–10, or as

clinically significant and/or functional status improvement of 30% or more. For interventional techniques, significant improvement has been defined as 50% reduction in pain scores and disability scores for evaluation purposes.

Before starting opioids, physicians should insure that the patient's expectations are realistic. The goal of opioid therapy for chronic non-cancer pain is rarely the elimination of pain, but rather an improvement in function or a reduction of pain intensity by at least 30%. Before starting opioids, a discussion with the patient about specific goals related to pain reduction and functional improvement should address any unrealistic expectations. These goals, once established should be documented in the patient's record; they are critical in determining that opioids are effective and should be monitored over time (54).

4.1 Recommendations
It is essential to establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: good)

5.0 Assessment Of Effectiveness Of Opioid Therapy

The effectiveness of various types of opioids must be clearly defined. The evidence for various types of opioids is described as follows.

1. Nociceptive pain — Opioids showed only small to moderate benefits for nociceptive pain for improving function and relieving pain on a short-term basis of 3 months or less. If opioids are required, patients generally respond to moderate doses after failure of alternative techniques and non-opioid management (1,49-58,62,68,73,76,90,91,132,302-316).

2. Neuropathic pain — Opioids showed only small to moderate benefits for neuropathic pain (1,49-58,73,90,132,303,317-319). However, it is the general belief that opioids are resistant in neuropathic pain and these patients may require higher opioid doses in combination with tricyclic antidepressants or anticonvulsants.

3. Widespread soft tissue pain — The benefit of the weak opioid tramadol for fibromyalgia was small. Other pain-relief options should be considered (54).

4. Headache and other problems — Opioids are not usually indicated for migraine or tension headaches, or for patients with functional gastrointestinal problems (316).

Multiple manuscripts, systematic and compre-

hensive reviews, and guidelines have been published evaluating the effectiveness and safety of opioids (1,49-58,62,68,73,76,90,91,132,302-319). With extensive review as shown in Part 1 (1), it was concluded that the short-term effectiveness of opioids is fair, whereas long-term effectiveness of opioids is limited or poor. There is also fair evidence for lack of significant difference in effectiveness or adverse effects between long-acting and short-acting opioids. The evidence for improvement in quality of life parameters is fair for short-term and poor for long-term. There is no published evidence for opioid rotation.

An evaluation of individual drugs also showed variable evidence with lack of available evidence for hydrocodone, fair for short-term, and poor for long-term for oxycodone, morphine, and fentanyl. The evidence for tramadol is fair in osteoarthritis. The evidence for methadone, oxymorphone, hydromorphone, tapentadol, codeine, and buprenorphine is limited for either short-term or long-term improvement.

An evaluation of the effectiveness, adverse effects, and indications in special populations showed the evidence is fair for short-term and poor for long-term in the elderly, poor in children, adolescents, and in patients with generalized anxiety disorder, depression, and high risk psychological disorders such as personality disorders.

5.1 Recommendations
1. Clinicians must understand the effectiveness and adverse consequences of long-term opioid therapy in chronic non-cancer pain and its limitations. (Evidence: fair for short-term, limited for long-term)
2. The long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting or moderate doses of long-acting opioids, as there is no significant difference between long-acting and short-acting opioids for their effectiveness or adverse effects. (Evidence: fair)
3. A trial of opioid rotation may be considered for patients requiring escalating doses. (Evidence: limited)
4. It is recommended that contraindications to opioid use in chronic non-cancer pain must be evaluated including respiratory instability, acute psychiatric instability, uncontrolled suicide risk, active or history of alcohol or substance abuse, confirmed allergy to opioid agents, coadministration of drugs capable of inducing life-limiting drug interaction,

concomitant use of benzodiazepines, active diversion of controlled substances, and concomitant use of heavy doses of central nervous system depressants, such as benzodiazepines. (Evidence: fair to limited)

6.0 INFORMED DECISION-MAKING

Informed decision-making with appropriate consent is not only essential but mandatory. A discussion about potential benefits, adverse effects, complications, and risks helps the physician and patient make a joint decision on whether to proceed with the opioid therapy (54). There have been substantial descriptions in reference to informed consent and treatment agreements and their effectiveness (1,320-327).

The following must be explained to patients and understood by patients before starting on opioids:
1) Opioids are used to improve the ability to be active and reduce pain, if appropriate criteria are met, in conjunction with or without various other modalities of treatments including cognitive behavioral therapy, behavior modification, therapeutic exercise program, increased activity, positive attitudes, physical therapy, psychotherapy, other drug therapy, or interventional techniques.
2) Opioids may help on a short-term basis, but they have substantial risks.
3) Common side effects include nausea (28%), constipation (26%), drowsiness (24%), dizziness (18%), dry-skin/itching (15%), and vomiting (15%) (54). However, these side effects can be minimized by slowly increasing the dose of the drug and starting a bowel regimen to manage constipation which may be the most long-lasting side effect of all. More serious complications include the effect on driving, respiratory depression, drug dependency, drug addiction, hormonal deficiency, fatigue, weakness, impotency, sexual dysfunction, etc., overdose, and death. Patients and physicians must take these complications and adverse consequences very seriously. Managing side effects through polypharmacy and the combination of various sedative hypnotics may not be useful.
4) The development of tolerance, dependency, addiction, and hyperalgesia are a major concern. Although the majority of patients believe that they can not develop addiction, many patients believe they develop tolerance and request higher doses believing that they are entitled for increase in doses and frequency with continued pain manage-

ment. However, physicians must educate patients on common aspects of addiction, hyperalgesia, and medication adjustment with emphasis on low dose or no opioid therapy and multidisciplinary management.

5) Abrupt stoppage of medication results in withdrawal states. Opioids overdoses are common, often resulting in various morbidities including death. Mixing opioids with alcohol or sedative drugs, such as antianxiety drugs and sleeping medications increase the risk of overdose significantly. Patients must understand the signs of overdosage.

6) Drugs prescribed to one patient may be disastrous to another person. Thus, medication should be safely secured by patients and never shared.

The informed consent and treatment agreement often includes clear descriptions of medication use and abuse, as well as the consequences for violating the contract, which are as follows:

1) One prescribing doctor and one designated pharmacy
2) Urine/serum drug screening when requested
3) No early refills and no medications called in
4) If medications are lost or stolen, then a police report could be required before considering additional prescriptions.

Additional items to be included in an agreement are listed in Table 4.

Overall, there is fair evidence to support the use of treatment agreements. Though in non-randomized studies (325), one found that treatment agreements

Table 4. *Sample controlled substance agreement.*

We are committed to doing all we can to treat your chronic pain condition. In some cases, controlled substances are used as a therapeutic option in the management of chronic pain and related anxiety and depression, which is strictly regulated by both state and federal agencies. This agreement is a tool to protect both you and your physician by establishing guidelines, within the laws, for proper controlled substance use. The words "we" and "our" refer to the facility, and the words "I", "you", "your", "me", or "my" refer to you, the patient.

1.   i. I understand that chronic opioid therapy has been associated with not only addiction and abuse, but also multiple medical problems including the suppression of endocrine function resulting in low hormonal levels in men and women which may affect mood, stamina, sexual desire, and physical and sexual performance.

    ii. For female patients: If I plan to become pregnant or believe that I have become pregnant while taking this medication, I am aware that, should I carry the baby to delivery while taking these medications; the baby will be physically dependent upon opioids. I will immediately call my obstetrician and this office to inform them of my pregnancy. I am also aware that opioids may cause a birth defect, even though it is extremely rare.

    iii. I have been informed that long-term and/or high doses of pain medications may also cause increased levels of pain known as opioid induced hyperalgesia (pain medicine causing more pain) where simple touch will be predicted as pain and pain gradually increases in intensity and also the location with hurting all over the body. I understand that opioid-induced hyperalgesia is a normal, expected result of using these medicines for a long period of time. This is only treated with addition of non-steroidal anti-inflammatory drugs such as Advil, Ibuprofen, etc., or by reducing or stopping opioids.

    iv. I understand that physical dependence is not the same as addiction. I am aware physical dependence means that if my pain medicine use is markedly decreased, stopped, or reversed by some of the agents mentioned above, I will experience a withdrawal syndrome. This means I may have any or all of the following: runny nose, yawning, large pupils, goose bumps, abdominal pain and cramping, diarrhea, irritability, aches throughout my body, and a flu-like feeling. I am aware that opioid withdrawal is uncomfortable, and could even result in heart attack, stroke, or death.

    v. I am aware that tolerance to analgesia means that I may require more medicine to get the same amount of pain relief. I am aware that tolerance to analgesia does not seem to be a big problem for most patients with chronic pain; however, it has been seen and may occur to me. If it occurs, increasing doses may not always help and may cause unacceptable side effects. Tolerance or failure to respond well to opioids may cause my doctor to choose another form of treatment, reduce the dose, or stop it.

2.   i. All controlled substances must come from the physician whose signature appears below or during his/her absence, by the covering physician, unless specific authorization is obtained for an exception.

    ii. I understand that I must tell the physician whose signature appears below or during his/her absence, the covering physician, all drugs that I am taking, have purchased, or have obtained, even over-the-counter medications. Failure to do so may result in drug interactions or overdoses that could result in harm to me, including death.

    iii. I will not seek prescriptions for controlled substances from any other physician, health care provider, or dentist. I understand it is unlawful to be prescribed the same controlled medication by more than one physician at a time without each physician's knowledge.

Table 4 (cont.). *Sample controlled substance agreement.*

iv. I also understand that it is unlawful to obtain or to attempt to obtain a prescription for a controlled substance by knowingly misrepresenting facts to a physician or his/her staff or knowingly withholding facts from a physician or his/her staff (including failure to inform the physician or his/her staff of all controlled substances that I have been prescribed).

3. All controlled substances must be obtained at the same pharmacy where possible. Should the need arise to change pharmacies, our office must be informed. The pharmacy that you have selected is:
_____ Phone:_____

4. i. You may not share, sell, or otherwise permit others, including your spouse or family members, to have access to any controlled substances that you have been prescribed.

   ii. Early refills will not be given. I will not consume excessive amount (I will follow prescribed instructions) and remain compliant to all aspects of treatment. Renewals are based upon keeping scheduled appointments. Please do not make phone calls for change in prescriptions unless you develop side effects or early refills and do not phone for refills after hours or on weekends.

   iii. Medication changes will not be made between appointments unless medically necessary, which will be determined by the physician.

5. Unannounced pill counts, random urine or serum, or planned drug screening may be requested from you and your cooperation is required. Presence of unauthorized substances in urine or serum toxicology screens may result in your discharge from treatment by the facility and its physicians and staff.

6. I will not consume excessive amounts of alcohol in conjunction with controlled substances. I will not use, purchase, or otherwise obtain any other legal drugs except as specifically authorized by the physician whose signature appears below or during his/her absence, by the covering physician, as set forth in Section 1 above. I will not use, purchase, or otherwise obtain any illegal drugs, including marijuana, cocaine, etc. I understand that driving while under the influence of any substance, including a prescribed controlled substance or any combination of substances (e.g., alcohol and prescription drugs), which impairs my driving ability, may result in DUI charges.

7. Medications or written prescriptions may not be replaced if they are lost, stolen, get wet, are destroyed, left on an airplane, etc. If your medication has been stolen, it will not be replaced unless explicit proof is provided with direct evidence from authorities. A report narrating what you told the authorities is not enough.

8. In the event you are arrested or incarcerated related to legal or illegal drugs (including alcohol), refills on controlled substances will not be given.

9. I understand that failure to adhere to these policies may result in cessation of therapy with controlled substances prescribed by this physician and other physicians at the facility and that law enforcement officials may be contacted.

10. I also understand that the prescribing physician has permission to discuss all diagnostic and treatment details, including medications, with dispensing pharmacists, other professionals who provide your health care, or appropriate drug and law enforcement agencies for the purpose of maintaining accountability.

11. I affirm that I have full right and power to sign and to be bound by this agreement, that I have read it, and understand and accept all of its terms. A copy of this document has been given to me.

_____
Patient's full name

_____   _____
Patient's signature   Date

_____   _____
Physician's signature   Date

improve compliance (326), while another found that primary-care physicians were more willing to prescribe opioids to patients if the pain medicine physician also signed an agreement ("tri-lateral contract") (327).

Informed consent or agreements also mandate that multiple random evaluations, including pill counts and UDT, must be performed. Furthermore, based on the state regulation, evaluation of prescription drug patterns are monitored by state controlled substance monitoring programs.

6.1 Recommendations

A robust agreement which is followed by all parties is essential in initiating and maintaining opioid therapy, as such agreements reduce overuse, misuse, abuse, and diversion. (Evidence: fair)

7.0 Initial Treatment

Initiation of treatment is based on evaluation of stratification of risk, knowledge and understanding of opioids, initiation with low-dose, short-acting, opioid therapy, and titration during an 8 to 12 week period.

7.1 Stratification of Risk

Stratification of risk for patients initiated or maintained on chronic opioid therapy is crucial to prevent misuse and abuse. These principles may also be applied for patients who are treated for acute pain management, but also have other risk factors and for whom pain may become chronic. Chronic opioid therapy has been defined as therapy lasting for at least 90 days, on a daily, or on a near daily basis (50,328). Consequently, all guidelines recommend that before initiating chronic opioid therapy for any patient and in high-risk patients for acute pain therapy, a clinician should conduct a history, physical examination, and appropriate testing, including an assessment of risk of substance abuse, misuse, or addiction. Chou et al (50) provided strong recommendation with low-quality evidence. In addition, they also recommended that a benefit to harm evaluation including a history, physical examination, and appropriate diagnostic testing, which should be performed and documented before initiation and on an on-going basis during chronic opioid therapy. Atluri et al (40) describe risk stratification of patients into different categories as the first step. The risk stratification is justified in all patients due to the significant proportion of misuse and abuse, which may range as high as 50% (50,150,207-214,329). Chou et al (50) described that risk stratification pertaining to outcomes associated with abuse liability of opioids—misuse, abuse, addiction, and diversion — is a vital but relatively undeveloped skill for many clinicians (50,330).All clinicians prescribing opioids, however, should be knowledgeable about the risk factors for opioid abuse. Moreover, it is also essential to perform an assessment of risks for opioid-associated adverse effects, given their high prevalence (50,331), even though it is difficult to perform, often time consuming, and without any reliable evidence of tools. Atluri et al (40) described the 3 cornerstones for responsible prescribing or stratifying patients by using screening tools into high, medium,

and low-risk groups; monitoring patients by using urine drug screening, prescription monitoring programs, and pill counts; and lastly, establishing dose limits.

Atluri et al (40) described that stratification of patients into different risk categories requires the use of existing screening tools designed specifically to screen for opioid misuse (subjective tools like Screener and Opioid Assessment for Patients with Pain (SOAPP) (332), Pain Medication Questionnaire (PMQ) (333), Prescription Drug Use Questionnaire-Patient Version (PDUQp) (334), or objective tools like Addiction Behaviors Checklist (ABC) (214), Diagnosis, Intractability, Risk Efficacy (DIRE) Score (335), and the tool by Atluri and Sudarshan (211) to classify patients as high-risk, medium-risk, and low-risk. They described that objective tools may be better than subjective tools. Solanki et al (77) and Sehgal et al (79) concluded that there was no single screening tool that can be applied universally. Similarly, Chou and Huffman also (51) concluded that most of the studies evaluating the screening tools had methodological flaws. However, some believe that screening tools may play an important role in curbing abuse.

In risk stratification, it is important to utilize multiple models incorporating psychological and behavioral factors to explain the pain experience (336). Positive psychology has highlighted the importance of personal resources in adapting to stressful situations. Thus, resilience has been defined as the ability to adapt to stressful circumstances and has been strongly associated with decreased perceptions of stress (337). Some also have defined resilience as a multidimensional construct composed of a constitutional variable such as temperament and personality accompanied by specific skills (338). Others (339) have observed that resilience can be seen as synonymous with reduced vulnerability (340), with the ability to adapt to adversity (341), or coping (342,343). In general, resilience is associated with less depression and greater wellbeing and mental health (338,339,344). Thus, Ramírez-Maestre et al (336) showed that adjustment to chronic pain is mainly explained by psychological variables such as resilience, pain acceptance, and coping, not the length of time in pain. Resilience prevents patients with chronic spinal pain from suffering emotional distress, because higher levels of resilience are associated with lower levels of depression and anxiety. The study showed that resilience is an important resource for recovery from distress for individuals with chronic spinal pain. Furthermore, the study also concluded positive personality characteristics could play a crucial role in patient adjustment and that clinicians

should take into account the positive path to improved capacity in order to better understand the chronic pain experience.

Based on the present evidence, regardless of use of screening tools, patients may be classified into 3 categories as follows:

♦ Low risk — Low risk patients include those with a definable physical pathology; objective signs and reliable symptoms; clinical correlation with diagnostic testing including MRI, physical examination, and interventional diagnostic techniques; with or without mild psychological comorbidities; with or without mild coexisting medical disorders; no or well defined and controlled personal or family history of alcoholism or substance abuse; age of 45 or greater; high levels of pain acceptance and active coping strategies; and well-motivated patients with willingness to participate in multimodal therapy and attempting to function at normal levels.

♦ Medium risk — Medium risk patients include those with significant pain problems with objective signs and symptoms confirmed by radiological evaluation, physical examination, or diagnostic interventions; with moderate psychological problems, well-controlled by medical therapy; moderate coexisting medical disorders well controlled by medical therapy and which are not affected by chronic opioid therapy such as central sleep apnea; those who develop mild tolerance but not hyperalgesia without physical dependence or addiction; past history of personal or family history of alcoholism or substance abuse; involvement of more than 3 regions of the body; with defined pathology with moderate levels of pain acceptance and coping strategies; and willing to participate in multimodal therapy and attempting to function in their normal daily lives.

♦ High-risk — High-risk patients include those with widespread pain without objective signs and symptoms (involvement of more than 3 regions of the body); aberrant drug-related behavior; history of misuse, abuse, addiction, diversion, dependency, tolerance and hyperalgesia and alcoholism; with major psychological disorders; age of less than 45; HIV related pain; high levels of pain exacerbation and low levels of coping strategies; unwilling to participate in multimodal therapy; and not functioning close to a near normal lifestyle.

The patients may be stratified into these categories with or without various tools, but with proper history, examination, and monitoring by PDMPs, UDT, and simple psychological evaluation.

7.2 Understanding Opioids

Table 5 shows commonly used opioids, and Table 6 shows commonly used benzodiazepines available in the United States with various generic and brand names. As illustrated in these tables, these drugs are available with multiple names. Consequently they may have multiple interactions with drugs (53,345-364). The literature is highly variable on combinations of acetaminophen and the total dose of acetaminophen. However on January 13, 2011, the Food and Drug Administration (FDA) announced that there is no data that indicates that taking more than 325 mg of acetaminophen per dosage unit provides more pain relief (345). Further, the FDA has stated that the maximum daily dose of acetaminophen be less than 4,000 mg for acute pain and 2,000 mg per day for chronic pain. The present consensus appears to be taking around 2,000 mg of acetaminophen per day (346-350,360). With recommended low-dose therapy, this should not be an issue unless patients take acetaminophen over the counter. Thus, they should be instructed not to use products with acetaminophen or take additional acetaminophen. Lower doses have been recommended specifically for tramadol and acetaminophen combinations as well as in patients with hepatic abnormalities and alcoholics.

Acetaminophen toxicity causes the majority of cases of acute renal failure in the United States (346,347). Sub-clinical liver toxicity has been shown to occur with doses below 4 grams per day (347,348). Alcohol also competes for the same metabolic pathway as acetaminophen placing heavy drinkers at higher risk for toxicity. Chronic alcohol use is an independent risk factor for mortality in acetaminophen poisoning (349).

7.3 Dose Limits

With overwhelming evidence for the misuse, abuse, and limited efficacy of chronic opioid therapy, the rationale for high-dose opioids is being re-examined (40,49-55,57,98,181,363). Generally, it is believed that patients who do not respond to a low or medium-dose of opioids will not respond to larger doses although individual circumstances also exist (40). In 2007, the state of Washington issued interagency guidelines that include the daily dose should not exceed 120 mg of morphine equivalent dose. The guidelines by APS and AAPM in 2009 defined the

Table 5. *Opioids with various generic and brand names available in the United States.*

DRUG (GENERIC NAME)	BRAND NAME(S)
Hydrocodone	
Hydrocodone with acetaminophen	Anexsia®, Co-Gesic®, Hycet®, Liquicet®, Lorcet®, Lorcet Plus®, Lortab®, Maxidone®, Norco®, Polygesic®, Stagesic®, Vicodin®, Vicodin ES®, Xodol®, Zamicet®, Zolvit®, Zydone®
Hydrocodone with ibuprofen	Vicoprofen®, Ibudone®
Hydrocodone with aspirin	Lortab ASA
Oxycodone	
Oxycodone HCL	OxyContin®, Oxy-IR®, Roxicodone®
Oxycodone HCL with acetaminophen	Endocet®, Percocet®, Percocet-Demi®, Tylox®, Roxicet®
Oxycodone HCL/ ASA	Endodan®, Percodan®, Percodan-Demi®, Roxiprin®
Oxycodone HCL with ibuprofen	Combunox®
Morphine	
Morphine sulfate	Avinza®, Kadian®, MS Contin®, MSIR®, Oramorph®, Rescudose®, Roxanol®
Morphine and Naltrexone	Embeda®
Fentanyl (transdermal)	Duragesic®, Actiq®, Fentora TM, Lazanda, Onsolis
Methadone HCL	Dolophine®, Methadose®
Hydromorphone HCL	Dilaudid®, Exalgo®, Hydrostat®, Palladone®
Oxymorphone	Opana®, Numorphan®
Codeine	
Codeine monohydrate/sulphate trihydrate	Codeine
Codeine phosphate/acetaminophen/ caffeine	Tylenol® (No. 1, 2, 3)
Codeine phosphate/acetaminophen without caffeine	Empracet®
Pentazocine HCL	Talwin®, Talxin NX®, Talacen®
Meperidine	Demerol®
Tramadol	
Tramadol	Rybix®, Ryzolt®, Ultram®, Ultram ER®
Tramadol/ Acetaminophen	Ultracet®
Dronabinol	Marinol®
Buprenorphine	Buprenex®, Subutex®, Suboxone®, Norspan®
Tapentadol	Nucynta®, Nucynta ER®

"high doses" to 100 mg morphine equivalent dose (51). The Canadian Guidelines in 2010 identified 200 mg morphine equivalent dose as a watchful dose (54). However, there has been only limited data verifying the safety of these recommended doses, especially in high-risk patients. Franklin et al (181) showed the effectiveness of dose limitation with reduction in dosage, frequency, and death rate. In addition, 5 studies showed that the rate of overdose was directly proportional to the prescribed opioid dose (87,135,364-366).

Bohnert et al (87) in a national sample of Veterans Health Administration patients revealed that there was a dose-response relationship between the maximum daily prescribed dose of opioids and the risk of opioid overdose deaths. The overdose death rate for patients receiving a dose of less than 20 mg morphine equivalent dose was 0.11 per 1,000 compared to those getting more than 100 mg morphine equivalent dose, for whom the death rate was 1.24. This difference was even higher in those with a history of substance

Table 6. *Benzodiazepines with various generic and brand names available in the United States.*

DRUG (GENERIC NAME)	BRAND NAME (S)
Alprazolam	Xanax®, Niravam®
Chlordiazepoxide	Librium®
Clonazepam	Klonopin®
Clorazepate	Tranxene®
Diazepam	Valium®, Valrelease®
Estazolam	ProSom®
Flurazepam	Dalmane®,
Lorazepam	Ativan®
Midazolam	Versed®
Oxazepam	Serax®
Quazepam	Doral®
Temazepam	Restoril®
Triazolam	Halcion®

abuse with 0.54% versus 2.9%. Based on these results, the authors concluded that the risk of opioid overdose increased when the opioid dose was equivalent to 50 mg morphine equivalent dose or higher. Dunn et al (135) in a population from a health maintenance organization (HMO) in Washington State, reported a 9-fold increase in opioid overdoses in patients receiving high dose opioids (> 100 mg morphine equivalent dose) when compared to those getting low dose (< 20 mg morphine equivalent dose). There was a 3.7-fold increase in overdose events in patients receiving doses between 50 to 99 mg morphine equivalent doses versus those getting less than 20 mg morphine equivalent dose. Paulozzi et al (364) found that compared to patients receiving lower opioid doses or no opioid prescriptions, the risk of overdose was greater if daily opioid doses were above 40 mg morphine equivalent dose. Braden et al (366) found that patients in Arkansas receiving morphine equivalent doses of more than 120 mg per day were more likely to have drug-related encounters than those getting lower doses. Gomes et al (365) found that patients from Ontario's Public Drug Plan receiving very high doses (> 400 mg morphine equivalent dose) and high doses (200 to 400 morphine equivalent dose) had a much higher overdose death rate than those getting moderate doses (< 200 mg morphine equivalent dose). Moreover, they also showed that in very high and high dose patients the opioid-related mortality rates were 9.94 per 1,000

population for very high and 7.92 for high. However, the opioid-related mortality rate was 1.63 per 1,000 in those with moderate doses. In addition, the overall death rate from any cause was much higher in patients receiving opioids (20.05) when compared to those who were not receiving any opioids (4.0) per 1,000 population. Franklin et al (181) showed that appropriate guidelines with dose limitation considering 120 mg morphine equivalent doses as high dose reduced overall opioids per day by 27% and long-acting Schedule II opioids by 37% in the proportion of the workers on doses of greater than 120 mg per day morphine equivalent dosage. Moreover, the number of deaths was reduced by 50% from 2009 to 2010. Rome et al (363) in a report of outcomes of a chronic non-cancer pain rehabilitation program according to opioid use and status at admission stratified the participants into non-opioid grouping in 221 patients, low-dose (< 41 mg per day) in opioid users in 71 patients, and high-dose (> 41 mg per day, an average of 137.48 mg per day) in opioid users in 64 patients. The outcomes at discharge showed that patients taking higher doses reported significantly greater catastrophizing and greater pain severity than the non-opioid group. Two other studies conducted in the worker's compensation population also showed similar results (367,368). Adverse events were also reported more commonly at higher daily doses (369,370). Pascual et al (369) showed the increasing frequency of adverse effects of high dose tramadol (over 400 mg) compared with lower doses, with 2 patients ex-

periencing seizures. Huse et al (370) in a randomized trial showed that attention deficit was more common during morphine treatment compared to placebo, which was more pronounced when a higher dose was taken. Other studies (98,296,370-372) have shown that there was a dose-dependent relationship between chronic opioid use, specifically with high doses and sleep disorders. Ballantyne and Mao (296) in 2003 indicated that doses higher than 100 mg of morphine equivalent dose per day have not been validated in clinical trials and should be considered excessive.

The above studies illustrate the dose-related effects at 40 mg morphine equivalent dose (364), 50 mg morphine equivalent dose (87,135), 120 mg morphine equivalent dose (177,366), and 200 mg morphine equivalent dose (365). Thus far, it appears that all the

available literature correlates increasing mortality with increasing doses. In addition, several studies have demonstrated that for patients with severe pain on high opioid doses, tapering resulted in reduced pain and improved mood (54,363,373-375).

In 2008, opioid pain relievers were involved in 14,800 drug overdose deaths in the United States compared to 11,500 of 27,500 fatal unintended drug overdose deaths in 2007 — an increase of 3,300 in just one year (34). Consequently, based on statistics, it has been concluded that opioid analgesics contributed to fatalities based on opioid abuse and increases, doctor shopping, and other aspects of drug abuse as illustrated in Figure 3. The Centers for Disease Control and Prevention (CDC) (34) also reported the percentage of prescription drug overdoses by risk group in the United States.

* Age-adjusted rates per 100,000 population for OPR deaths, crude rates per 10,000 population for OPR abuse treatment admissions, and crude rates per 10,000 population for kilograms of OPR sold.

Fig. 3. *Rates of opioid pain reliever overdose death, opioid pain relief treatment admissions, and kilograms of opioid pain relievers sold – United States, 1999-2010.*

Source: Centers for Disease Control and Prevention. Vital signs: Overdoses of prescription opioid pain relievers – United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011; 60:1487-1492 (83).

This concluded that approximately 80% of prescribed low doses (less than 100 mg morphine equivalent dose per day) were by a single practitioner, accounting for an estimated 20% of all prescription overdoses (Fig. 4). In contrast, among the remaining 20% of patients, 10% were prescribed high doses greater than 100 mg of morphine equivalent dose per day (85-87) of opioids by single prescribers accounting for an estimated 40% of the prescription opioid overdoses (87,135). The remaining 10% of patients seeing multiple doctors and typically involved in drug diversion contributed to 40% of overdoses (376).

Multiple studies in the literature have reported an association between opioid prescribing and overall health status, with increased disability, medical costs, subsequent surgery, and continued or late opioid use (23,31,33,36,167,293-295,367,368,377-387). Overall, epidemiologic studies are less positive with regards to improvement in function and quality of life with opioids in chronic pain patients (23,31,33,36,49,55,56,57,133,167,293-295,367,368,377-389). In fact, in an epidemiologic study from Denmark by Breivik et al (23) where opioids were prescribed liberally for chronic pain, it was demonstrated that in patients receiving opioids, pain was worse, health care utilization was higher, and activity levels were lower compared to a matched cohort of chronic pain patients not using opioids. Eriksen et al (32) also reported worse pain, higher health care utilization, and lower activity levels

in opioid-treated patients compared to matched cohort of chronic pain patients not using opioids. Sjøgren et al (33) in a population based cohort study on chronic pain and the role of opioids, showed that the odds of recovery from chronic pain were almost 4 times higher among individuals not using opioids compared with individuals using opioids. In addition, they also showed that use of strong opioids was associated with poor health-related quality of life and higher risk of death.

Therefore, we have reached a consensus on the following: low-dose is up to 40 mg of morphine equivalent dose, moderate dose is 41 to 90 mg morphine equivalent dose, and high dose is any dose after 91 or higher mg of morphine equivalent dosages. These doses are lower than described by the CDC, which shows >100 mg as high dose and Washington State guidelines, which show 120 mg as the high dose, but considered reasonable, based on current evidence, and a cautious approach, specifically when a patient is receiving multimodal therapy.

7.4 Initiation with Low-Dose Opioid Therapy

A physician should follow the principles of prescribing a low opiate dose as reasonably achievable or ALARA (as low as reasonably achievable) similar to radiation exposure guidelines to provide therapeutic effect without major side effects (390-402).

Low dose therapy may be effective with a reduction in the rate of complications, side effects, and ad-


Fig. 4. *Percentage of patients and prescription drug overdoses, by risk group – United States.*

Source: Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses – a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012; 61:10-13 (34).

Table 7. *Recommended low-dose opioid therapy for select opioids showing starting doses and maintenance doses.*

Opioid	Recommended Starting Dose For Opioid-Naive Patients	Recommended Starting Dose For Opioid Exposed Patient's High Doses Leading To High Risks.	Recommended Maintenance Dose
Hydrocodone	5 to 10 mg, 2 to 3 times daily	5 to 10 mg, 3 to 4 times daily	30 to 40 mg for 24 hours
Morphine			
Morphine Immediate Release	Not recommended	10 mg, 2 to 3 times	30 to 60 mg per day
Morphine Sustained Release	Not recommended	15 to 30 mg twice daily	60 to 90 mg daily
Oxycodone			
Oxycodone	5 to 10 mg, 2 to 3 times daily	5 to 10 mg, 3 to 4 times daily	30 to 40 mg per day
Oxycodone Sustained Release	Not recommended	10 mg for 12 hours	30 to 60 mg for 24 hours
Methadone	Not recommended	2 to 5 mg, 2 to 3 times daily	10 to 30 mg per day
Transdermal Fentanyl	Not recommended	12.5 to 25 mcg q72h	25 to 50 mcg per 72 hours
Hydromorphone			
Hydromorphone Immediate Release	2 mg bid or tid	2 to 4 mg, 2 to 3 times daily	8 to 16 mg per day
Hydromorphone Sustained Release	Not recommended	5 mg to 10 mg, 2 times daily	20 to 40 mg daily
Codeine	15 mg bid or tid	30 mg bid to qid	120 to 160 mg daily
Oxymorphone			
Oxymorphone Immediate Release	5 mg bid or tid	5 to 10 mg 2 to 3 times daily	30 to 40 mg per day
Oxymorphone Sustained Release	Not recommended	10 mg q12h	40 to 60 mg per day
Tramadol			
Tramadol	50 mg bid or tid	50 mg 3 to 4 times daily	150 to 300 mg per day
Tramadol Sustained Release	Not recommended	200 mg daily	200 to 350 mg per day

verse effects, specifically when opioid therapy is combined with other modalities including interventional techniques. Consideration of higher dosage requires careful reassessment of the pain and risk of misuse, and frequent monitoring with evidence of improved patient outcomes if at all necessary.

Based on the available literature recommended low-dose therapy is shown in Table 7 for chronic non-cancer pain along with a description of dosing thresholds for selected opioids (1,49-55,58).

Thus, for mild to moderate pain, first line therapy should start with tramadol, codeine, or hydrocodone. For second line mild to moderate pain therapy, clinicians should start with hydrocodone or oxycodone. For severe pain, first line therapy may start with hydrocodone, oxycodone, hydromorphone, or morphine, with second line therapy leading to fentanyl and if absolutely necessary, the third line therapy for severe pain with methadone or buprenorphine (54). The literature illustrates that codeine and tramadol may have a lower abuse risk than more potent opioids (54,403-405).

Abuse rates measured from Drug Abuse Warning Network Data (DAWN) (405) showed that codeine and other low-potency opioids have low ratios of abuse to prescription use, related to oxycodone, hydromorphone, and hydrocodone. Tramadol also has a low risk of addiction, and experimental studies suggest that it has fewer psychoactive effects than other opioids (403,404). However, neither tramadol nor codeine are readily tolerated by the majority of patients long-term. In chronic pain management settings, the majority of patients have allegedly used these drugs (Tramadol and codeine) and refuse to try them. Oxycodone, hydrocodone, and hydromorphone have been shown to have higher abuse liability than other opioids (54,405-411). Butler et al (407) in a study of the 14 most desirable opioid formulations, found that prescription opioid misusers ranked controlled release oxycodone, immediate release hydromorphone, and oxycodone as the most desirable. Cicero et al (408) in a national surveillance study of addiction experts, law enforcement agencies, and poison control centers, identified hydrocodone and oxycodone (immediate release and controlled) as by far the most commonly abused opioids in the United States.

Morphine can cause toxicity in patients with re-

nal dysfunction (54,406). It has been shown that M-6 glucuronide, an active metabolite of morphine, accumulates in the serum of patients and causes central nervous system and respiratory depression. The degree of accumulation was related to the morphine dose and the extent of renal impairment (412).

Fentanyl, 80-100 times as potent as morphine can cause significant central nervous system and respiratory depression and also has been shown to contribute to numerous overdose deaths (54,349,413-416). Fentanyl was a contributing cause in 100 overdose deaths in Ontario between 2002 and 2004 with fentanyl intoxication being the sole cause of death in 54 of the patients with therapeutic and illicit use of fentanyl including chewing and ingesting fentanyl patches (414). In addition, fentanyl-laced heroin appeared simultaneously in various parts of the United States, beginning in 2005, with 55 drug overdose cases resulting in 12 deaths in the first half of 2006 (415). Fentanyl toxicity was related to 92% of the fentanyl-related deaths and is attributed partially due to cytochrome P450 3A4*1B and 3A5*3 variant alleles, resulting in variable fentanyl metabolism. Furthermore, the FDA (417), in July of 2005, issued a public health advisory calling attention to an increase in the number of fentanyl-patch-related overdoses and deaths, particularly among patients ignoring the product's boxed warnings and instructions for use. Another issue has been that up to 10% of Caucasians lack the enzyme CYP450 2D6 that converts codeine to morphine. Consequently, when switching from codeine to fentanyl, regardless of the codeine dose, caution must be exercised as patients may have little or no opioid tolerance (418-421).

In reference to methadone, even though it has not been shown to be more effective than other opioids, it has been used extensively in the United States and associated with multiple adverse consequences including prolonged QT interval (50,51,54,60,99,101,102,153,308,313,361,422-427). Methadone has been associated with numerous overdose deaths in pain patients with analgesic use increasing sharply in the United States, with a 1,293% increase from 1997 to 2007 (31). Methadone is also, however, dispensed in methadone clinics with very little regulation and supervision.

Meperidine is not recommended in chronic pain settings due to adverse neurological events resulting in confusion and seizures with long-term treatment secondary to accumulation of toxic metabolite Normeperidine. The adverse events with meperidine are also increased with long-term use, renal insufficiency, and concurrent benzodiazepine use (428).

Long-acting opioids are generally provided in high dose formulations, increasing the risk of abuse and overdose. Furthermore, long-acting opioids can easily be converted to immediate release by crushing or biting the tablet. Thus, OxyContin 80 mg tablet is equivalent to 16 Percocet tablets (54).

7.5 Titrate

Opioid medications must be started at low doses and titrated gradually to higher amounts if necessary. All attempts must be made to maintain patients on lower doses, including use of other drugs. Combinations of short- and long-acting, and high doses of long-acting opioids must be prescribed with extreme caution.

7.6 Recommendations

1. Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs with appropriate monitoring to provide effective relief and avoid side effects. (Evidence: fair for short-term effectiveness, limited for long-term effectiveness)
2. We are recommending up to 40 mg of morphine equivalent doses as low dose, 41 to 90 mg of morphine equivalent dose as a moderate dose, and greater than 91 mg of morphine equivalence as high doses. (Evidence: fair)
3. In reference to long-acting opioids, titration must be carried out with caution and overdose and misuse must be avoided. (Evidence: good)
4. Methadone is recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (Evidence: limited)

8.0 Adherence Monitoring

The role of adherence monitoring with various tools has been described as part of the initial evaluation. This must be continued through the treatment phase with PDMPs, UDT, pill counts, and behavioral assessment during each visit. Adherence monitoring is dependent on risk stratification. Monitoring based on risk stratification is illustrated in Figure 5 (40).An algorithmic approach to UDT is illustrated in Figure 6. However, regulations with stricter criteria take priority over these algorithmic approaches.

Aberrant drug-related behaviors, include alteration of prescriptions or the route of delivery, doctor shop-

Chronic Pain

Screening Tool

May Use
Objective screening tools: DIREScore, ABC Checklist, screening tool by Atluri & Sudarshan.

-or-

Subjective screening tools: SOAPP, PDUQ_P, PMQ.

Low Risk

+UDS: every 1-2 years
+PMP: twice per year
+Use > 50 mg MED if needed*
+If aberrant behaviors are demonstrated, counseling must be done to address them and if the behavior is unchanged, opioid use must be seriously reconsidered.

Medium Risk

+UDS: every 6-12 months
+PMP: 3 times a year
+Use > 50 mg MED occasionally*
+If aberrant behaviors are demonstrated, counseling must be done to address them and if the behavior is unchanged, opioid use must be seriously reconsidered.

High Risk

+UDS: every 3-6 months
+PMP: 4 times per year
+Avoid Opioids or use *very* low doses (10 mg MED)
+Avoid dose escalations
+Use > 50 mg MED RARELY*
+Patients displaying aberrant behaviors should be weaned off opioids

*MED - Morphine Equivalent Dose

Fig. 5. *Risk stratification and adherence monitoring.*

Reproduced with permission from: Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: An algorithmic, evidence-based approach. Pain Physician 2012; 15:ES177-ES189.

Fig. 6. *Algorithmic steps in urine drug testing in chronic pain.*
Reproduced with permission from: Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J. Urine drug testing in chronic pain. Pain Physician 2011; 14:123-143 (226).

ping or accessing opioids from other sources, multiple unauthorized dose escalations, drug seeking behavior with focus on certain types of opioids and benzodiazepines, loss of prescriptions, requests for early refills, aggressive complaining, staff harassment, complaining about other patients, questioning rights and responsibilities, repeated withdrawal symptoms, exacerbation of underlying mood or anxiety disorders, alcohol use, poor social functioning, loss of job and loss of activities of daily living, emphatic views on opioid medication and illicit drugs as well as legalization of illicit drugs.

8.1 Recommendations

1. Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days and yearly thereafter. (Evidence: fair)
2. In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT and PMDPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (Evidence: fair)

9.0 Monitoring and Managing Side Effects

Multiple side effects, including effect on driving, sedation, constipation, and breathing specifically in patients with respiratory disorders, must be monitored.

Adverse effects have been commonly reported with nausea in 28%, constipation in 26%, somnolence/drowsiness in 24%, dizziness/vertigo in 18%, dry-skin/itching/pleuritis in 15%, and vomiting in 15% of patients on relatively high-dose opioids. Low-dose opioids, however, have been accompanied by lesser complications (1,54,346-354,403-477). The majority of these adverse effects are resolved with continued treatment and dose adjustments. However, constipation may not be resolved and requires a bowel regimen. Furthermore, with long-term therapy and high doses, other complications may be noted including hypogonadism, neuroendocrine dysfunction, sleep disorders, and hyperalgesia (1,54,403-477). Other effects which are seen in less than 10% of the population include dry mouth, headache, sexual dysfunction, hot flashes, loss of appetite, abdominal pain, fatigue, sleeplessness/insomnia, sweating, blurred vision/confusion, muscle contractions, diarrhea, ataxia, edema, difficulty urinating, restless legs, application site reaction, heartburn, anxiety, and weakness (54). The majority of these com-

plications do resolve except for sexual dysfunction and fatigue, which increase with long-term treatment with hormonal imbalances. However, the complications are more frequent, longer lasting, and severe in long-term high-dose opioid therapy. Peripheral edema, though observed in a small proportion of patients, could be a major issue. Neuroendocrine abnormalities with erectile dysfunction must be taken into consideration and explained to the patient, with appropriate referral when indicated. Similarly sleep apnea and opioid-induced hyperalgesia (OIH) must be handled appropriately (1).

Neuroendocrine abnormalities and erectile dysfunction can be experienced with long-term opioid therapy in as many as 11% of the patients (296,430-435). Some outdated reports essentially state that patients taking opioid medications reported better sexual function, which was likely an improvement of well-being (429). Thus, in the short-term, a patient may notice improvement in many aspects including sexual function, but in the long-term, opioids may cause neuroendocrine dysfunction.

Smith and Elliott (478) described that opioid-induced androgen deficiency (OPIAD) is characterized by the presence of inappropriate low levels of gonadotrophin (follicle-stimulating hormone and leuteinizing hormone) leading to the inadequate production of sex hormones, particularly testosterone. Symptoms that may manifest in patients with OPIAD include reduced libido, erectile dysfunction, fatigue, hot flashes, and depression. Physical findings may include reduced facial and body hair, anemia, decreased muscle mass, weight gain, and osteopenia or osteoporosis. While the literature regarding OPIAD remains limited, OPIAD can have a significant negative impact on the quality of life of opioid users. Thus, clinicians should anticipate the potential for its occurrence whenever long-term opioid prescribing is undertaken and develop appropriate management strategies. Once diagnosed, treatment for OPIAD may be offered utilizing a number of androgen replacement therapy options including a variety of testosterone preparations and, for female patients, dehydroepiandrosterone (DHEA) supplementation.

OIH and the treatment of breakthrough pain in chronic non-cancer pain are controversial issues. OIH is more commonly accepted even though the concept of breakthrough pain continues to be mired in beliefs of pseudoaddiction and undertreatment of pain. The evidence is in contrast to the fact that pain may be essentially overtreated in many countries, specifically

Vol. II Page 249

with opioids, even though overall there may also be an undertreatment of pain in some regions and segments of the population (75,95).

Opioids can aggravate not just central sleep apnea, but frequently may also significantly aggravate obstructive sleep apnea. High opioid doses may contribute to sleep movement disorders including myoclonus and sometimes choreiform movement, and in combination with benzodiazepines and other drugs may significantly contribute to oxygen desaturation (326,437-449). The most serious complications include respiratory depression and death, which may occur when initial doses are too high, opioids are titrated too rapidly, or opioids are combined with other drugs that are associated with respiratory depression or that may potentiate opioid-induced respiratory depression such as benzodiazepines or abuse of opioids with or without other drugs (472-477). Many herbals and over-the-counters, including diphenhydramine preparations can contribute to a dose-dependant respiratory depression. Patients with sleep apnea or with other pulmonary conditions may be at a higher risk for respiratory depression and opioids should be initiated, titrated, and monitored closely with as low a dose as possible. Furthermore, high opioid doses may contribute to sleep movement disorders including sleep apnea.

Part 1 with evidence assessment showed that the evidence is fair for existence of opioid hyperalgesia with chronic opioid therapy (1,75,95). However, debate continues on this aspect. Tompkins and Campbell (454) questioned whether OIH is clinically relevant or an extraneous research phenomenon, nothing that not all evidence supports the clinical importance of OIH, and that there is some doubt as to whether the phenomenon exists at all. Overall, there is growing evidence to support the presence and consequences of opioid hyperalgesia, along with the benefits of reducing opioid doses or weaning patients off of opioids.

Among the multiple side effects, constipation is one of the most common opioid-related adverse effects (331). Constipation may become a major issue with continued exposure to opioids in a significant proportion of patients. In addition, in older adults or other patients with additional reasons to develop constipation, constipation may be more frequent and also problematic. Consequently, a physician should consider the initiation of a bowel regimen even before the development of constipation and definitely after the development of constipation. Even though the evidence for bowel regimen is anecdotal, regimens, including increased fluid and fiber intake, stool softeners, and laxatives, are often simple and effective. Multiple publications have evaluated opioid antagonists in the prevention or treatment of opioid-induced bowel dysfunction (479,480), but the evidence is insufficient to recommend such antagonists to prevent bowel dysfunction.

During dosage titration in a trial of opioid therapy, advise the patient to avoid driving a motor vehicle or dangerous activities such as use of heavy machinery, until a stable dosage is established, it is certain the opioid does not cause sedation; and when taking opioids with alcohol, benzodiazepines, or other sedating drugs (54). When assessing safety to drive in patients on long-term opioid therapy, consider factors that could impair cognition and psychomotor ability, such as a consistently severe pain rating, disordered sleep, and concomitant medications that increase sedation (54).

Wilhelmi and Cohen (481) in a focused review described a framework for "driving under the influence of drugs" policy for the opioid-using driver. Driving under the influence of drugs is a term used to designate the action of driving an automobile after the consumption of drugs or medications other than alcohol that interfere with the capacity to operate a vehicle safely. Unlike recreational drugs, prescription medications, specifically opioids and benzodiazepines, pose a unique challenge to those attempting to harness their benefits, yet protect the driving public. Wilhelmi and Cohen (481) concluded that a sizable percentage of the driving public has detectable levels of opioids within their bodies. The best available evidence demonstrates psychomotor impairment following acute administration of opioids or an increase in opioid dosage, but impairment diminishes with chronic, stable opioid dosage. Thus, it is essential to take into account the evidence in chronic pain patients when balancing the benefit of pain relief against the need for public roadway protection. Similarly, policy makers also should take into account these issues during drafting driving under the influence of drugs legislation.

9.1 Recommendations

1. It is essential to monitor for side effects and manage them appropriately including discontinuation of opioids if indicated. (Evidence: fair)
2. Constipation must be closely monitored and a bowel regimen be initiated as soon as deemed necessary. (Evidence: good)
3. It is recommended that a policy of driving under the influence of drugs be developed and monitored during initiation of therapy, changes in the dosages, and addition of other centrally acting agents. (Evidence: good)

10.0 THE FINAL PHASE

After initiation of opioid therapy and stable maintenance for 8 to 12 weeks with appropriate outcomes, it is essential to arrive at a conclusion to either continue or to discontinue the opioids.

If the patient continues with persistent pain or there is new pain, a comprehensive evaluation must be repeated or a referral may be made. Similarly, if there is any indication of abuse, misuse, lack of analgesia, lack of activity, adverse effects, or aberrant behavior, the physician must taper the drug therapy and discontinue. Alternate modalities must be pursued at this stage.

Opioid therapy is continued if appropriate analgesia and functional status is achieved either with opioid therapy alone or in conjunction with other modalities. Minimal requirements for continued opioid therapy are analgesia of at least 30%, and/or activity improvement of 30% without misuse/abuse, or major adverse effects. However, if treatment is successful, one may attempt to wean from opioids if necessary. If necessary to continue, monitoring must be continued and the patient be discharged either with improvement or with any deficiencies.

Patients on high doses, obtaining inadequate analgesia, and with other issues may be converted to sublingual buprenorphine. Daitch et al (482) described conversion of chronic pain patients from full opioid agonists to sublingual buprenorphine. They described the results from clinical records of 100 chronic pain patients with 60 men and 44 women aged 21 to 78 and who had previously been treated with opioid agonist drugs. They were converted to buprenorphine sublingual tablet form during the study. After initiation of buprenorphine sublingual therapy for more than 2 months, the mean pain scores on a scale from 0 to 10 decreased by 3 points. However, patient quality of life was not significantly affected by buprenorphine sublingual therapy. The success rate was highest for patients using morphine, oxycodone, and fentanyl before buprenorphine sublingual induction. These patient groups had a 3.7-point decrease in pain for those taking morphine, a 2.5-point decrease in pain for those taking oxycodone, and a 2.2-point decrease for those taking fentanyl. The smallest pain reduction was seen in the patient groups using oxymorphone. In addition, patients taking between 100 to 199 mg morphine equivalent per day experienced the greatest reduction (2.7 points) in pain scores. Patients taking between 200 to 299 mg of morphine equivalent before buprenorphine sublingual induction exhibited a decrease of over 2 points on average. Patients taking greater than 400 mg morphine

equivalent reported the smallest reduction in pain scores, on average a 1.1 point decrease.

In patients with dependency, office-based opioid dependence treatment may be provided. In a narrative review, Colson et al (483) described that office-based opioid dependence treatment is a viable alternative to methadone treatment or rehabilitation programs. However, office-based treatment of opioid dependency requires a special licensure from the DEA. Thus, for physicians providing opioid management of pain, the use of buprenorphine/naloxone is an important tool to consider for opioid dependence issues, which arise in treating chronic pain.

If it is required, tapering or discontinuation of opioid therapy may be considered; however, for a patient who has not been taking medication on a long-term basis, tapering or weaning is not necessary and discontinuation may be carried out. Tapering may be carried out slowly with a decrease by 10% of the original dose per week. This is generally well tolerated with minimal adverse physiological effects. However, some patients can be tapered or weaned more rapidly without any major problems over a 6 to 8 week period. During this period, if opioid abstinence syndrome is encountered, it is rarely medically serious, even though symptoms may be quite unpleasant. The symptoms of abstinence syndrome, including nausea, diarrhea, muscle pain, and myoclonus, can be managed with clonidine 0.1 to 0.2 mg orally every 6 hours or clonidine transdermal patch 0.1 mg - 24 hours weekly during the taper. Patients should be monitored often for significant hypotension and anticholinergic side effects. While rare, in some patients it may be necessary to slow the tapering and weaning timeline from weekly to monthly dosage adjustments. If the patient is not following the tapering dosages and abusing them, then tapering is going to be unsuccessful and patients must be referred to detoxification facilities or advised to do so.

Symptoms of mild opioid withdrawal occasionally may persist for 6 months after opioids have been discontinued. The physician may also consider using adjuvant agents such as antidepressants to manage irritability and sleep disturbance, or antiepileptics for neuropathic pain. However, physicians should be cautious and preferably not treat withdrawal symptoms with opioids or benzodiazepines once the weaning process or discontinuation of opioids is started. The patient may be referred for counseling or other support during the weaning period if there are significant behavioral issues. If such issues arise, the physician should refer the patient to a chemical dependency center for complicated withdrawal symptoms.

Physicians not trained in pain management may refer their patients with these issues to pain management specialists or addictionologists.

10.1 Recommendations

1. Chronic opioid therapy may be continued, with continuous adherence monitoring, modified at any time during this phase, with fair evidence showing effectiveness of opioids in well-selected populations, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects. (Evidence: fair)
2. Methadone is recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (Evidence: limited)
3. A trial of opioid rotation may be considered for patients requiring escalating doses. (Evidence: limited)
4. Chronic opioid therapy should be monitored for adverse effects and to manage them appropriately. (Evidence: good)

11.0 DOCUMENTATION

The physician should keep accurate and complete medical records, which include all aspects of interventional pain management and medical care. These comprise, but are not limited to:

- Medical history and physical examination
- Diagnostic, therapeutic, and laboratory results
- Evaluations and consultations
- Treatment objectives
- Discussion of risks, benefits, and limitations of treatments
- Details of different treatments and medications, including date, type, dosage, and quantity prescribed
- Instructions to the patient
- Periodic reviews of outcomes, including documentation of functional status, preferably using validated tools.

Records should remain current and be maintained in an accessible manner and readily available for review, not only for the physician and other members of the practice, but also for authorities.

To be in compliance with controlled substance laws and regulations required to prescribe, dispense, or administer controlled substances, the physician must have an active license in the state and comply with applicable federal and state regulations. Various licensure boards have

published regulations and recommendations for prescribing controlled substances. Physicians are advised to refer to those regulations for their respective state. Physicians should not prescribe scheduled drugs for themselves or immediate family except in emergency situations.

The following criteria should be considered carefully in providing controlled substances:

1. Complete initial evaluation, including history and physical examination
2. Psychological evaluation
3. Physiological and functional assessment, as necessary and feasible
4. Indications and medical necessity
5. The use of the lowest possible dose to provide adequate analgesia with minimum side effects should be the goal of opioid therapy
6. In general, do not combine opioids with sedative-hypnotics, benzodiazepines, or barbiturates for chronic, non-cancer pain unless there is a specific medical indication for the combination
7. Adherence to the controlled substance agreement with patients understanding the risks and benefits of controlled substances and the policy and regulations of the practitioner, including controlled substances being prescribed by only one practitioner and being obtained from only one pharmacy
8. Monitoring for drug abuse or diversion should be routine, and if confirmed, referral to rehabilitation centers may be made, with termination of prescriptions of controlled substances.

12.0 SUMMARY

The evidence synthesis and guidance preparation provides the following recommendations with 10 steps to opioid therapy:

12.1 Initial Steps of Opioid Therapy

- Comprehensive assessment and documentation is recommended before initiating opioid therapy, documentation of comprehensive history, general medical condition, psychosocial history, psychiatric status, and substance use history. (Evidence: good)
- Despite limited evidence for reliability and accuracy, screening for opioid use is recommended, as it will identify opioid abusers and reduce opioid abuse. (Evidence: limited)
- Prescription monitoring programs must be implemented due to regulations, AS they provide data on patterns of prescription usage, reduce prescrip-

Vol. II Page 252

tion drug abuse or doctor shopping, and PDMPs may reduce emergency room visits, drug overdoses, or deaths. (Evidence: good to fair)

- UDT must be implemented from initiation along with subsequent adherence monitoring, in an in-office setting with immunoassay and confirmation for accuracy with chromatography in select cases, to identify patients who are non-compliant or abusing prescription drugs or illicit drugs, and UDT may decrease prescription drug abuse or illicit drug use when patients are in chronic pain management therapy. (Evidence: good)

12.2 Establish Diagnosis

- Establish appropriate physical diagnosis and psychological diagnosis if available prior to initiating opioid therapy. (Evidence: good)
- Caution must be exercised in ordering various imaging and other evaluations, and only appropriate information in the realm of clinical relevance shall be provided by the treating physician to the patients when there is correlation of the symptoms with findings, to avoid increased fear, activity restriction, requests for increased opioids, and maladaptive behaviors. (Evidence: good)
- A pain management consultation, for non-pain physicians, if high-dose opioid therapy is being utilized. (Evidence: fair)

12.3 Establishing Medical Necessity

It is essential to establish medical necessity prior to initiation or maintenance of opioid therapy. (Evidence: good)

12.4 Establishing Treatment Goals

It is essential to establish treatment goals of opioid therapy with regard to pain relief and improvement in function. (Evidence: good)

12.5 Assessment of Effectiveness of Opioid Therapy

- Clinicians must understand the effectiveness and adverse consequences of long-term opioid therapy in chronic non-cancer pain and its limitations. (Evidence: fair for short-term, limited for long-term)
- The long-acting opioids in high doses are recommended only in specific circumstances with severe intractable pain that is not amenable to short-acting or moderate doses of long-acting opioids, as there is no significant difference between long-act-

ing and short-acting opioids for their effectiveness or adverse effects. (Evidence: fair)

- A trial of opioid rotation may be considered for patients requiring escalating doses. (Evidence: limited)
- It is recommended that contraindications to opioid use in chronic non-cancer pain must be evaluated including respiratory instability, acute psychiatric instability, uncontrolled suicide risk, active or history of alcohol or substance abuse, confirmed allergy to opioid agents, coadministration of drugs capable of inducing life-limiting drug interaction, concomitant use of benzodiazepines, active diversion of controlled substances, and concomitant use of heavy doses of central nervous system depressants, such as benzodiazepines. (Evidence: fair to limited)

12.6 Informed Decision-Making

A robust agreement which is followed by all parties is essential in initiating and maintaining opioid therapy as such agreements reduce overuse, misuse, abuse, and diversion. (Evidence: fair)

12.7 Initial Treatment

- Once medical necessity is established, opioid therapy may be initiated with low doses and short-acting drugs with appropriate monitoring to provide effective relief and avoid side effects. (Evidence: fair for short-term effectiveness, limited for long-term effectiveness)
- We are recommending up to 40 mg of morphine equivalent doses as low dose, 41 to 90 mg of morphine equivalent dose as a moderate dose, and greater than 91 mg of morphine equivalence as high doses. (Evidence: fair)
- In reference to long-acting opioids, titration must be carried out with caution and overdose and misuse must be avoided. (Evidence: good)
- Methadone is recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (Evidence: limited)

12.8 Adherence Monitoring

- Monitoring recommendation for methadone prescription is that an electrocardiogram should be obtained prior to initiation, at 30 days and yearly thereafter. (Evidence: fair)
- In order to reduce prescription drug abuse and doctor shopping, adherence monitoring by UDT

and PMDPs provide evidence that is essential to the identification of those patients who are non-compliant or abusing prescription drugs or illicit drugs. (Evidence: fair)

12.9 Monitoring and Managing Side Effects

- It is essential to monitor for side effects and manage them appropriately including discontinuation of opioids if indicated. (Evidence: fair)
- Constipation must be closely monitored and a bowel regimen be initiated as soon as deemed necessary. (Evidence: good)
- It is recommended that a policy of driving under the influence of drugs be developed and monitored during initiation of therapy, changes in the dosages, and addition of other centrally acting agents. (Evidence: good)

12.10 The Final Phase

- Chronic opioid therapy may be continued, with continuous adherence monitoring, modified at any time during this phase, with fair evidence showing effectiveness of opioids in well-selected populations, in conjunction with or after failure of other modalities of treatments with improvement in physical and functional status and minimal adverse effects. (Evidence: fair)
- Methadone and buprenorphine are recommended for use in late stages after failure of other opioid therapy and only by clinicians with specific training in the risks and uses. (Evidence: limited)
- A trial of opioid rotation may be considered for patients requiring escalating doses. (Evidence: limited)
- Chronic opioid therapy should be monitored for adverse effects and to manage them appropriately. (Evidence: good)

13.0 CONCLUSION

These guidelines were developed based on an extensive review of the literature, consensus among the panelists, and practice patterns. There are numerous fatalities with increasing therapeutic use and abuse, this may be related to a lack of understanding and education in the proper application of opioid therapy. Furthermore, the evidence supporting efficacy for use of opioids as a treatment for chronic non-cancer pain is fair for short-term to improve pain and function, whereas it is limited due to lack of literature in reference to long-term efficacy or effectiveness. For practitioners considering opioid use, multiple recommendations for opioid management are summarized. The majority of treatment recommendations are based on evidence consensus and practice patterns, rather than high quality evidence alone. Thus, opioids for chronic non-cancer pain should be reserved for select patients with moderate or severe pain that significantly affects function or quality of life. Appropriate evaluation, documentation, screening, and risk stratification is indicated from initiation through the continuation of opioid therapy.

In conclusion, the focus of these guidelines has been to objectively evaluate the evidence with the application of consensus and practice patterns to curb opioid abuse, misuse, and overuse, and at the same time maintain access to opioids for patients who are in need of them.

Conflicts of Interest:

Ten of the 55 authors provided information that they

Vol. II Page 254

received funding from the industry; however, of these, only 2 (less than 4%) were receiving funding from drug makers and with multidisciplinary authorships (18%) receiving funding for research or engaged in speaking from the industry.

Dr. Benyamin is a clinical investigator with Epimed and receives research support from Cephalon/Teva, Bio-Delivery Sciences International, Inc., Mundipharma Research GmbH & Co., AstraZeneca, Purdue Pharma, LP, and Theravance.

Dr. Burton is a consultant for Medtronic and Boston Scientific. He serves on the Speaker's Bureau for Johnson & Johnson, Archimedes, Cephalon, and Jazz.

Dr. Caraway is a consultant for Medtronic, Inc., Spinal Modulation, Inc., and Vertos, Inc.

Dr. Datta receives research support from Sucampo Pharmaceuticals and an honorarium from Smith and Nephew.

Dr. Deer is a consultant and research advisor for Bioness, Medtronic, St. Jude, Spinal Modulation, and Vertos.

Dr. Falco is a Consultant for St. Jude Medical Inc. and Joimax Inc.

Dr. Grider is an educational trainer for Vertos Medical

Dr. Hayek is a consultant for Boston Scientific.

Dr. Helm is a clinical investigator with Epimed and receives research support from Cephalon/Teva, AstraZeneca, and Purdue Pharma, LP.

Dr. Hirsch is a consultant for CareFusion and receives royalties for products related to vertebral augmentation. He also participated in an Aetrium focus group and received compensation.

Dr. A. Kaye is a speaker for Depomed, Inc.

Dr. Silverman is a Speaker for Purdue Pharma and Reckit Benckiser

Dr. Vallejo receives research support from Cephalon/Teva, BioDelivery Sciences International, Inc., Mundipharma Research GmbH & Co., AstraZeneca, Purdue Pharma, LP, and Theravance.

AUTHOR AFFILIATIONS

Note: All authors after the first author are listed in alphabetical order.

1. Laxmaiah Manchikanti, MD is Medical Director of the Pain Management Center of Paducah, Paducah, KY and Clinical Professor, Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY drm@asipp.org

2. Salahadin Abdi, MD, PhD is Chief, Division of Pain Medicine at Beth Israel Deaconess Medical Center, Brookline, MA, and Associate Professor of Anesthesiology, Harvard Medical School, Boston, MA. sabdi@bidmc. harvard.edu

3. Sairam Atluri, MD is Medical Director, Tri-State Spine Care Institute, Cincinnati, OH saiatluri@gmail.com

4. Carl C. Balog, MD is an interventional pain physician at Oregon Pain Associates, Portland, OR drcsaba@comcast.net

5. Ramsin M. Benyamin, MD is the Medical Director, Millennium Pain Center, Bloomington, IL, and Clinical Assistant Professor of Surgery, College of Medicine, University of Illinois, Urbana-Champaign, IL ramsinbenyamin@yahoo.com

6. Mark V. Boswell, MD, PhD is Chairman, Department of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY mark.boswell@louisville.edu

7. Keith R. Brown, PharmD is a pharmacist at Murray Calloway County Hospital, Murray, KY krbrownrph@aol.com

8. Brian M. Bruel, MD is Assistant Professor, Departments of Physical Medicine & Rehabilitation and Anesthesiology & Pain Management, McDermott Center for Pain Management, UTSW Spine Center, University of Texas Southwestern Medical Center, Dallas, TX bbruel@mdanderson.org

9. David A. Bryce, MD is from Advanced Pain Management, Madison, WI. tonys09@gmail.com

10. Patricia A. Burks, LPT is a licensed physical therapist at the Pain Management Center of Paducah, Paducah, KY clinicaldirector@thepainmd.com

11. Allen W. Burton, MD is a Professor and Chairman, Department of Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, TX awburton@houstonpainassociates.com

12. Aaron K. Calodney, MD is a Staff Physician and Director and Research Coordinator Implantable Therapies at NeuroCare Network, Tyler, TX aaroncalodney@me.com

13. David L. Caraway, MD is with St. Mary's Pain Relief Center, Huntington, WV carawaymd@aol.com

14. Kimberly A. Cash, RT is a Research Coordinator at the Pain Management Center of Paducah, Paducah, KY kcash@thepainmd.com

15. Paul J. Christo, MD is Associate Professor, Johns Hopkins University School of Medicine, Director, Multidisciplinary Pain Fellowship (2003-2011), Director, Blaustein Pain Treatment Center (2003-2008), Division of Pain Medicine, Department of Anesthesiology and Critical Care Medicine, Baltimore, MD. pchristo@jhmi.edu

16. Kim S. Damron, RN is a Nursing Administrator at the Pain Management Center of Paducah, Paducah, KY kim@thepainmd.com

Vol. II Page 255

17. Sukdeb Datta, MD is Medical Director, Laser Spine & Pain Institute, New York, NY sdattamd@gmail.com

18. Timothy R. Deer, MD is Medical Director, The Center for Pain Relief and Clinical Professor, Anesthesiology, West Virginia University School of Medicine, Charleston, WV doctdeer@aol.com

19. Sudhir Diwan, MD is Executive Director of The Spine and Pain Institute of New York. sudhir.diwan63@gmail.com

20. Ike Eriator, MD is Associate Professor of Public Health, Jackson State University, Jackson, MS, Director of the Pain Program, University of Mississippi Medical Center, Jackson, MS ikeijen@yahoo.com

21. Frank J.E. Falco, MD is Medical Director of the Mid Atlantic Spine & Pain Physicians of Newark, DE, Director, Pain Medicine Fellowship, Temple University Hospital, Philadelphia, PA, and Associate Professor, Department of PM&R, Temple University Medical School, Philadelphia, PA. cssm01@aol.com

22. Bert Fellows, MA is Director Emeritus of Psychological Services at the Pain Management Center of Paducah, Paducah, KY bert@thepainmd.com

23. Stephanie Geffert, MLIS is Director of Research and Education and Administrative Assistant at Mid Atlantic Spine & Pain Physicians of Newark, DE and Fellowship Coordinator at Temple University Hospital, Philadelphia, PA sgeffert@midatlanticspine.com

24. Christopher G. Gharibo, MD is Medical Director of Pain Medicine and Associate Professor of Anesthesiology and Orthopedics, Department of Anesthesiology, NYU Langone-Hospital for Joint Diseases, NYU School of Medicine, New York, NY. Cgharibo@usa.net

25. Scott E. Glaser, MD is the Medical Director of Pain Specialists of Greater Chicago, Burr Ridge, IL. sglaser@painchicago.com

26. Jay S. Grider, DO, PhD is Medical Director, UK Healthcare Pain Services, Division Chief, Pain and Regional Anesthesia and Associate Professor, Department of Anesthesiology, University of Kentucky, Lexington, KY jsgrid2@email.uky.edu

27. Haroon Hameed, MD is with the Department of Physical Medicine and Rehabilitation, The Johns Hopkins University School of Medicine, Baltimore, MD. hhameed1@jhmi.edu

28. Mariam Hameed, MD is with the Department of Physical Medicine and Rehabilitation, The Johns Hopkins University School of Medicine, Baltimore, MD mhameed1@jhmi.edu

29. Hans Hansen, MD is the Medical Director of The Pain Relief Centers, Conover, NC. hans@hippocrates.org

30. Michael E. Harned, MD is Assistant Professor, Department of Anesthesiology, Division of Pain Medicine, University of Kentucky, Lexington, KY. mharned@me.com

31. Salim M. Hayek, MD, PhD is Associate Professor, Department of Anesthesiology, Chief of the Division of Pain Medicine, University Hospitals of Cleveland, Cleveland, OH; and a member of the Outcomes Research Consortium, Cleveland, OH. Salim.hayek@uh-hospitals.org

32. Standiford Helm II, MD is Medical Director, The Helm Center for Pain Management, Laguna Hills, CA. drhelm@thehelmcenter.com

33. Joshua A. Hirsch, MD is Chief of Minimally Invasive Spine Surgery, Depts. of Radiology and Neurosurgery, Massachusetts General Hospital and Associate Professor of Radiology, Harvard Medical School, Boston, MA. hirsch@snisonline.org

34. Jeffrey W. Janata, PhD is Associate Professor of Psychiatry, Director, Behavioral Medicine Program University Hospitals of Cleveland Case Western Reserve University, Cleveland, OH jeffrey.janata@case.edu

35. Adam M. Kaye, PharmD is Clinical Professor, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA. akaye@pacific.edu

36. Alan D. Kaye, MD, PhD is Chairman and Professor, Dept of Anesthesia LSU Health Science Center, New Orleans, LA alankaye44@hotmail.com

37. David S. Kloth, MD is Medical Director of Connecticut Pain Care, Danbury, CT. dkmd@ctpaincare.com

38. Dhanalakshmi Koyyalagunta, MD is Associate Professor, Medical Director, Pain Management Center University of Texas, MD Anderson Cancer Center, Dept. of Anesthesiology & Pain Medicine, Houston, TX dkoyyala@mdanderson.org

39. Marion Lee, MD is Director of Centers for Pain Management, Tifton, GA painanswers@aol.com

40. Yogesh Malla, MD is an Interventional Pain Physician at the Pain Management Center of Paducah, Paducah, KY. Yogesh@thepainmd.com

41. Kavita N. Manchikanti, MD is a second year resident in Physical Medicine and Rehabilitation at the University of Kentucky, Lexington, KY kavita.manchikanti@gmail.com

42. Carla D. McManus, RN, BSN is a Nursing Administrator at the Pain Management Center of Paducah, Paducah, KY carla@thepainmd.com

43. Vidyasagar Pampati, MSc is a Statistician at the Pain Management Center of Paducah, Paducah, KY sagar@thepainmd.com

44. Allan T. Parr, MD is Medical Director, Premier Pain Center, Covington, LA alparr@alparr.com

Vol. II Page 256

45. Ramarao Pasupuleti, MD is Medical Director, Center for Pain Management, Bowling Green, KY rampasupuleti@yahoo.com

46. Vikram Patel, MD is Medical Director of ACMI Pain Care, Algonquin, IL. vikpatel1@yahoo.com

47. Nalini Sehgal, MD is Medical Director, Interventional Pain Program, University of Wisconsin School of Medicine and Public Health and Associate Professor, Department of Orthopedics and Rehabilitation Medicine, Madison, WI. Sehgal@rehab.wisc.edu

48. Sanford M. Silverman, MD is Medical Director of Comprehensive Pain Medicine, Pompano Beach, FL sanfordsilverman@cpmedicine.com

49. Vijay Singh, MD is Medical Director, Spine Pain Diagnostics Associates, Niagara, WI. vj@wmpnet.net

50. Howard S. Smith, MD is Professor and Academic Director of Pain Management for Albany Medical College Department of Anesthesiology, Albany, NY

51. Lee T. Snook, MD is Medical Director of Metropolitan Pain Management Consultants, Inc., Sacramento, CA. lsnook@pain-mpmc.com

52. Daneshvari R. Solanki, MD is Professor of Anesthesia and Pain Management, University of Texas Medical Branch, Galveston, TX. dsolanki@utmb.edu

53. Deborah H. Tracy, MD is Medical Director, Institute of Interventional Pain Management, Brooksville, FL. tracypain@tampabay.rr.com

54. Ricardo Vallejo, MD, PhD is Director of Research, Millennium Pain Center, Bloomington, IL; and Adjunct Professor of Biology, Illinois State University, Normal, IL. vallejo1019@yahoo.com

55. Bradley W. Wargo, DO is an interventional pain physician at the McFarland Clinic, Mary Greeley Medical Center, Ames, IA. bwargo@pol.net

REFERENCES

1. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Colson J, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJE, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen HC, Harned M, Hayek SM, Helm II S, Hirsch JA, Janata JW, Kaye AM, Kaye AD, Koyyalagunta D, Lee M, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel V, Pope JE, Sehgal N, Silverman SM, Singh V, Smith HS, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 1 – Evidence assessment. *Pain Physician* 2012; 15:S1-S66.

2. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope, and impact of spinal pain. *Pain Physician* 2009; 12:E35-E70.

3. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: A World Health Organization study in primary care. *JAMA* 1998; 280:147-151.

4. Institute of Medicine (IOM). *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. The National Academies Press, Washington, DC, 2011.

5. Martin BI, Turner JA, Mirza SK, Lee MJ, Comstock BA, Deyo RA. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006. *Spine (Phila Pa 1976)* 2009: 34:2077-2084.

6. Harkness EF, Macfarlane GJ, Silman AJ, McBeth J. Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. *Rheumatology (Oxford)* 2005; 44:890-895.

7. Freburger JK, Holmes GM, Agans RP, Jackman AM, Darter JD, Wallace AS, Castel LD, Kalsbeek WD, Carey TS. The rising prevalence of chronic low back pain. *Arch Intern Med* 2009; 169:251-258.

8. Hoy DG, Bain C, Williams G, March L, Brooks P, Blyth F, Woolf A, Vos T, Buchbinder R. A systematic review of the global prevalence of low back pain. *Arthritis Rheum* Jan 9. [Epub ahead of print] (2012).

9. Hoy DG, Protani M, De R, Buchbinder R. The epidemiology of neck pain. *Best Pract Res Clin Rheumatol* 2010; 24:783-792.

10. Reid KJ, Harker J, Bala MM, Truyers C, Kellen E, Bekkering GE, Kleijnen J. Epidemiology of chronic non-cancer pain in Europe: Narrative review of prevalence, pain treatments and pain impact. *Curr Med Res Opin* 2011; 27:449-462.

11. Bekkering GE, Bala MM, Reid K, Kellen E, Harker J, Riemsma R, Huygen FJ, Kleijnen J. Epidemiology of chronic pain and its treatment in The Netherlands. *Neth J Med* 2011; 69:141-153.

12. Langley PC. The prevalence, correlates and treatment of pain in the European Union. *Curr Med Res Opin* 2011; 27:463-480.

13. Tosato M, Lukas A, van der Roest HG, Danese P, Antocicco M, Finne-Soveri H, Nikolaus T, Landi F, Bernabei R, Onder G. Association of pain with behavioral and psychiatric symptoms among nursing home residents with cognitive impairment: Results from the SHELTER study. *Pain* 2012; 153:305-310.

14. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. *J Pain Symptom Manage* 2002; 23:131-137.

15. Eriksen J. Epidemiology of chronic non-malignant pain in Denmark. *Pain* 2003; 106:221-228.

16. Moulin DE, Clark AJ, Speechley M, Morley-Forster PK. Chronic pain in Canada – prevalence, treatment, impact and the role of opioid analgesia. *Pain Res Manag* 2002; 7:179-184.

17. Sjøgren P, Ekholm O, Peuckmann V, Grønbæk M. Epidemiology of chronic pain in Denmark: An update. *Eur J Pain* 2009; 13:287-292.

18. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. *Lancet* 1999; 354:1248-1252.

19. Eriksen J, Ekholm O, Sjøgren P, Rasmussen NK. Development of and recovery from long-term pain. A 6-year follow-up study of a cross-section of the adult Danish population. *Pain* 2004; 108:154-162.

20. Lawrence RC, Helmick CG, Arnett FC. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum*

1998; 41:778-799.

21. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: A review of the literature. *Pain* 1998; 77:231-239.

22. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. *J Pain* 2006; 7:281-289.

23. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. *Eur J Pain* 2006; 10:287-333.

24. Blyth FM, Rochat S, Cumming RG Creasey H, Handelsman DJ, Le Couteur DG, Naganathan V, Sambrook PN, Seibel MJ, Waite LM. Pain, frailty and comorbidity on older men: The CHAMP study. *Pain* 2008; 140:224-230.

25. Cassidy JD, Carroll LJ, Côté P. The Saskatchewan Health and Back Pain Survey. The prevalence of low back pain and related disability in Saskatchewan adults. *Spine (Phila Pa 1976)* 1998; 23:1860-1867.

26. Côté P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults. *Spine (Phila Pa 1976)* 1998; 23:1689-1698.

27. Leboeuf-Yde C, Nielsen J, Kyvik KO, Fejer R, Hartvigsen J. Pain in the lumbar, thoracic or cervical regions: Do age or gender matter? A population-based study of 34,902 Danish twins 20–71 years of age. *BMC Musculoskeletal Disorders* 2009; 10:39.

28. Côté P, Cassidy JD, Carroll L. The factors associated with neck pain and its related disability in the Saskatchewan population. *Spine (Phila Pa 1976)* 2000; 25:1109-1117.

29. Manchikanti L, Benyamin R, Datta S, Vallejo R, Smith HS. Opioids in chronic noncancer pain. *Expert Rev Neurother* 2010; 10:775-789.

30. Deyo RA, Smith DH, Johnson ES, Donovan M, Tillotson CJ, Yang X, Petrik AF, Dobscha SK. Opioids for back pain patients: Primary care prescribing patterns and use of services. *J Am Board Fam Med* 2011; 24:717-727.

31. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective. *Pain Physician* 2010; 13:401-435.

32. Eriksen J, Sjøgren P, Bruera E, Ekholm

O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. *Pain* 2006; 125:172-179.

33. Sjøgren P, Grønbæk M, Peuckmann V, Ekholm O. A population-based cohort study on chronic pain: The role of opioids. *Clin J Pain* 2010; 26:763-769.

34. Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses – a U.S. epidemic. *MMWR Morb Mortal Wkly Rep* 2012; 61:10-13.

35. Ballantyne J, LaForge K. Opioid dependence and addiction during opioid treatment of chronic pain. *Pain* 2007; 129:235-255.

36. US Government Accountability Office: Report to Congressional Requesters. Prescription Pain Reliever Abuse. December 2011. www.gao.gov/assets/590/587301.pdf

37. Toblin RL, Mack KA, Perveen G, Paulozzi LJ. A population-based survey of chronic pain and its treatment with prescription drugs. *Pain* 2011; 152:1249-1255.

38. Okie S. A flood of opioids, a rising tide of deaths. *N Engl J Med* 2010; 363:1981-1985.

39. Manchikanti L, Helm S, Fellow B, Pampati V, Boswell MV. Epidemic of opioid use in the United States. *Pain Physician* 2012; 15:ES9-ES38.

40. Atluri SL, Akbik H, Sudarshan G. Prevention of opioid abuse in chronic non-cancer pain: An algorithmic, evidence-based approach. *Pain Physician* 2012; 15:ES177-ES189.

41. United States Department of Justice, Drug Enforcement Administration. Automation of Reports and Consolidated Orders System (ARCOS). Springfield, VA, 2011. www.deadiversion.usdoj.gov/arcos/index.html

42. Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. *JAMA* 2011; 305:1299-1301.

43. Governale L. Outpatient prescription opioid utilization in the U.S., years 2000 – 2009. Drug Utilization Data Analysis Team Leader, Division of Epidemiology, Office of Surveillance and Epidemiology. Presentation for U.S. Food and Drug Administration, July 22, 2010.

44. SDI Vector One ®: National.

45. IMS Institute for Healthcare Informatics. The use of medicines in the United States: Review of 2011. April 2012.

www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf

46. Report of the International Narcotics Control Board 2008. New York, United Nations, 2009. www.incb.org/pdf/annual-report/2008/en/AR_08_English.pdf

47. Pizzo PA, Clark NM. Alleviating suffering 101 – pain relief in the United States. *N Engl J Med* 2012; 366:197-199.

48. A fresh view of opioids. *The BackLetter* 2011; 26:4, 37.

49. Reinecke H, Sorgatz H; German Society for the Study of Pain (DGSS). S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. *Schmerz* 2009; 23:440-447.

50. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009; 10:113-130.

51. Chou R, Huffman L. *Use of Chronic Opioid Therapy in Chronic Non-cancer Pain: Evidence Review.* American Pain Society, Glenview, IL, 2009. www.ampainsoc.org/library/pdf/Opioid_Final_Evidence_Report.pdf

52. British Pain Society. Opioids for persistent pain: Good practice. A consensus statement prepared on behalf of the British Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Faculty of Addictions of the Royal College of Psychiatrists. London, UK, *The British Pain Society*, January 2010.

53. Agency Medical Directors Group. Interagency Guidelines on Opioid Dosing for Chronic Non-cancer Pain: An educational aid to improve care and safety with opioid therapy. 2010 Update.
www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf

54. National Opioids Use Guideline Group (NOUGG). Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain, Recommendations for Practice, Version 5.6. April 30, 2010.
http://nationalpaincentre.mcmaster.ca/documents/opioid_guideline_part_b_

Vol. II Page 258

v5_6.pdf

55. Trescot AM, Helm S, Hansen H, Benyamin R, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of Interventional Pain Physicians' (ASIPP) guidelines. *Pain Physician* 2008; 11:S5-S62.

56. Chou R, Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. *Ann Intern Med* 2007; 147:505-514.

57. Sorgatz H, Maier C. Nothing is more damaging to a new truth than an old error: Conformity of new guidelines on opioid administration for chronic pain with the effect prognosis of the DGSS S3 guidelines LONTS (long-term administration of opioids for non-tumor pain). *Schmerz* 2010; 24:309-312.

58. National Opioids Use Guideline Group (NOUGG). Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain, Executive Summary and Background, Version 4.5. April 30, 2010.

59. Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: Guidelines revisited. *Curr Opin Anaesthesiol* 2010; 23:598-601.

60. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. *J Pain* 2009; 10:131-146.

61. Boulanger L, Wu N, Chen SY, Nagar S, Fraser K, Bernauer MJ, Zhao Z, Zhao Y. Predictors of pain medication selection among patients diagnosed with fibromyalgia. *Pain Pract* 2012; 12:266-275.

62. Letter to Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, U.S Food and Drug Administration, from Physicians for Responsible Opioid Prescribing RE Docket No. FDA-2011-D-0771, Draft Blueprint for Prescriber Education for Long-Acting/Extended Release Opioid Class-Wide Risk Evaluation and Mitigation Strategies. 2 December, 2011.

63. Manchikanti L, Pampai S, Damron KS, Cash KA, McManus CD, Fellows B. Identification of doctor shoppers with

64. KASPER: A comparative evaluation over a decade in Western Kentucky. *J KY Med Assoc* 2012; 110:13-21.

64. Fauber J. UW a force in pain drug growth. *JSOnline*. April 2, 2011.

65. Fauber J. Academics profit by making the case for opioid painkillers. *MedPage Today*. April 3, 2011.

66. Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis. *BMJ* 2011; 343:d5142.

67. Fauber J. Painkiller boom fueled by networking. *Journal Sentinel*, Feb. 18, 2012. http://m.jsonline.com/more/news/139609053.htm

68. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. *Ann Intern Med* 2007; 146:116-127.

69. Zerzan JT, Morden NE, Soumerai S, Ross-Degnan D, Roughead E, Zhang F, Simoni-Wastila L, Sullivan SD. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. *Med Care* 2006; 44:1005-1010.

70. Gupta A, Patton C, Diskina D, Cheatle M. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors. *Pain Physician* 2011; 14:383-389.

71. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. *CMAJ* 2009; 181:891-896.

72. Toblin RL, Paulozzi LJ, Logan JE, Hall AJ, Kaplan JA. Mental illness and psychotropic drug use among prescription drug overdose deaths: A medical examiner chart review. *J Clin Psychiatry* 2010; 71:491-496.

73. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, Sehgal N, Shah RV, Benyamin RM, Vallejo R, Fellows B, Christo PJ. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. *Pain Physician* 2011; 14:91-121.

74. Colson J, Koyyalagunta D, Falco FJE, Manchikanti L. A systematic review of observational studies on the effectiveness of opioid therapy for cancer pain. *Pain Physician* 2011; 14:E85-E102.

75. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive

review of opioid-induced hyperalgesia. *Pain Physician* 2011; 14:145-161.

76. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. *Pain Physician* 2011; 14:E133-E156.

77. Solanki DR, Koyyalagunta D, Shah RV, Silverman SM, Manchikanti L. Monitoring opioid adherence in chronic pain patients: Assessment of risk of substance misuse. *Pain Physician* 2011; 14:E119-E131.

78. Koyyalagunta D, Bruera E, Solanki D, Nouri KH, Burton AW, Perez MT, Bruel B, Manchikanti L. A systematic review of randomized trials of the effectiveness of opioids for cancer pain. *Pain Physician* 2012; 15:ES39-ES58.

79. Sehgal N, Manchikant L, Smith HS. Prescription opioid abuse in chronic pain: A review of opioid abuse predictors and strategies to curb opioid abuse. *Pain Physician* 2012; 15: ES67-ES92.

80. Vallejo R, Barkin RL, Wang VC. Pharmacology of opioids in the treatment of chronic pain syndromes. *Pain Physician* 2011; 14E343-E360.

81. Koyyalagunta D, Burton AW, Toro MP, Driver L, Novy DM. Opioid abuse in cancer pain: Report of two cases and presentation of an algorithm of multidisciplinary care. *Pain Physician* 2011; 14:E361-E371.

82. Ballantyne JC. Opioid analgesia: Perspectives on right use and utility. *Pain Physician* 2007; 10:479-491.

83. Centers for Disease Control and Prevention. Vital signs: Overdoses of prescription opioid pain relievers – United States, 1999-2008. *MMWR Morb Mortal Wkly Rep* 2011; 60:1487-1492.

84. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. *J Gen Intern Med* 2011; 26:1450-1457.

85. Edlund MJ, Martin BC, Fan MY, Braden JB, Devries A, Sullivan MD. An analysis of heavy utilizers of opioids for chronic noncancer pain in the TROUP Study. *J Pain Symptom Manage* 2010; 40:279-289.

86. Katz N, Panas L, Kim M, Audet AD, Bilansky A, Eadie J, Kreiner P, Paillard FC, Thomas C, Carrow G. Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006. *Pharmacoepidemiol Drug Safety* 2010; 19:115-123.

87. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC. Association between opioid prescribing patterns and opioid overdose-related deaths. *JAMA* 2011; 305:1315-1321.

88. Ohio Department of Health. Ohio drug poisoning fact sheet: Epidemic of prescription drug overdoses in Ohio. www.healthyohioprogram.org/vipp/drug/dpoison.aspx

89. Lanier WA. Prescription opioid overdose deaths—Utah, 2008–2009. Presented at: *59th Annual Epidemic Intelligence Service Conference.* Atlanta, GA, April 19-23, 2010.

90. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. *Can Med Assoc J* 2006; 174:1589-1594.

91. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. *Pain* 2004; 112:372-380.

92. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980-2008. NCHS data brief, no. 81. National Center for Health Statistics, Hyattsville, MD, 2011.

93. Sullivan MD. Limiting the potential harms of high-dose opioid therapy: Comment on "Opioid dose and drug-related mortality in patients with non-malignant pain." *Arch Intern Med* 2011; 171:691-693.

94. Katz MH. Long-term opioid treatment of nonmalignant pain: A believer loses his faith. *Arch Intern Med* 2010; 170:1422-1424.

95. Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-cancer pain: Fact, fiction, or abuse. *Pain Physician* 2011; 14:E103-E117.

96. Macintyre PE, Loadsman JA, Scott DA. Opioids, ventilation and acute pain management. *Anaesth Intensive Care* 2011; 39:545-558.

97. Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W. An analysis of the root causes for opioid-related overdose deaths in the United States. *Pain Med* 2011; 12:S26-S35.

98. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, Shilling KC. Chronic opioid use is a risk fac-

tor for the development of central sleep apnea and ataxic breathing. *J Clin Sleep Med* 2007; 3:455-461.

99. Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: Prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. *Fundam Clin Pharmacol* 2011; 25:503-510.

100. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H. Opioid maintenance patients with QTc prolongation: Congenital long QT syndrome mutation may be a contributing risk factor. *Drug Alcohol Depend* 2010; 112:216-219.

101. Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: Risk factors in pain and addicted populations. *J Gen Intern Med* 2010; 25:305-309.

102. Mayet S, Gossop M, Lintzeris N, Markides V, Strang J. Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? *Drug Alcohol Rev* 2011; 30:388-396.

103. Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, Psaty BM, Von Korff M. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med* 2010; 25:310-315.

104. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. *Arch Intern Med* 2010; 170:1968-1976.

105. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: How physicians can help control it. *J Clin Psychiatry* 2011; 72:589-592.

106. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. *Lancet* 2012; 379:55-70.

107. National Health Services, The National Treatment Agency for Substance Misuse. Addiction to Medicine. An investigation into the configuration and commissioning of treatment services to support those who develop problems with prescription-only or over-the-counter medicine. May 2011. www.nta.nhs.uk/uploads/addictiontomedicinesmay2011a.pdf

108. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: A description of the high prevalence of accidental fatalities involving prescribed medications. *Am J Addict*

2009; 18:5-14.

109. Unintentional Drug Poisoning in the United States. Centers for Disease Control and Prevention. July 2010. www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf

110. De Maddalena CD, Bellini M, Berra M, Meriggiola C, Aloisi AM. Opioid induced hypogonadism. Why and how to treat it. *Pain Physician* 2012; 15:ES111-ES118.

111. McCarberg BH. Chronic pain: Reducing costs through early implementation of adherence testing and recognition of opioid misuse. *Postgrad Med* 2011; 123:132-139.

112. Wysowski DK, Schober SE, Wise RP, Kopstein A. Mortality attributed to misuse of psychoactive drugs, 1979-88. *Public Health Rep* 1993; 108:565-570.

113. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban–rural status and by drug type. *Pharmacoepidemiol Drug Saf* 2008; 17:997-1005.

114. U.S. General Accounting Office. Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion. Washington, DC, U.S. General Accounting Office, 2002. Report No. GAO-02-634.

115. U.S. Department of Justice Drug Enforcement Administration. Prescription drug monitoring programs. www.deadiversion.usdoj.gov/faq/rx_monitor.htm

116. Federation of State Medical Boards of the US. Model guidelines for the use of controlled substances for the treatment of pain: A policy document of the Federation of State Medical Boards of the United States, Inc. Dallas, TX, 1998.

117. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. *JAMA* 2000; 284:428-429.

118. Brennan F, Carr DB, Cousins M. Pain management: A fundamental human right. *Anesth Analg* 2007; 105:205-221.

119. Frasco PE, Sprung J, Trentman TL. The impact of the Joint Commission for Accreditation of Healthcare Organizations pain initiative on perioperative opiate consumption and recovery room length of stay. *Anesth Analg* 2005; 100:162-168.

120. Cohen MZ, Easley MK, Ellis C, Hughes B, Ownby K, Rashad BG, Rude M, Taft E, Westbrooks JB. JCAHO cancer pain management and the JCAHO's pain standards: An institutional challenge. *J*